Skip to main content
eLife logoLink to eLife
. 2020 Nov 18;9:e63042. doi: 10.7554/eLife.63042

Regulation of RUVBL1-RUVBL2 AAA-ATPases by the nonsense-mediated mRNA decay factor DHX34, as evidenced by Cryo-EM

Andres López-Perrote 1, Nele Hug 2, Ana González-Corpas 1, Carlos F Rodríguez 1, Marina Serna 1, Carmen García-Martín 1, Jasminka Boskovic 1, Rafael Fernandez-Leiro 1, Javier F Caceres 2, Oscar Llorca 1,
Editors: Andreas Martin3, John Kuriyan4
PMCID: PMC7707835  PMID: 33205750

Abstract

Nonsense-mediated mRNA decay (NMD) is a surveillance pathway that degrades aberrant mRNAs and also regulates the expression of a wide range of physiological transcripts. RUVBL1 and RUVBL2 AAA-ATPases form an hetero-hexameric ring that is part of several macromolecular complexes such as INO80, SWR1, and R2TP. Interestingly, RUVBL1-RUVBL2 ATPase activity is required for NMD activation by an unknown mechanism. Here, we show that DHX34, an RNA helicase regulating NMD initiation, directly interacts with RUVBL1-RUVBL2 in vitro and in cells. Cryo-EM reveals that DHX34 induces extensive changes in the N-termini of every RUVBL2 subunit in the complex, stabilizing a conformation that does not bind nucleotide and thereby down-regulates ATP hydrolysis of the complex. Using ATPase-deficient mutants, we find that DHX34 acts exclusively on the RUVBL2 subunits. We propose a model, where DHX34 acts to couple RUVBL1-RUVBL2 ATPase activity to the assembly of factors required to initiate the NMD response.

Research organism: Human

Introduction

RUVBL1 and RUVBL2 are two closely related AAA-type ATPases that assemble as hetero-hexameric structures made of alternating subunits and comprising six ADP/ATP-binding domains (Figure 1A). RUVBL1 and RUVBL2 contain a unique domain II (DII) that protrudes from one side of the hexamer and defines two distinct faces of the ring, named ATPase-face and DII-face hereafter (Cheung et al., 2010; Ewens et al., 2016; Gorynia et al., 2011; Lakomek et al., 2015; López-Perrote et al., 2012). DII domains comprise an oligonucleotide/oligosaccharide-binding (OB) fold domain (DII external) that connects to the hexameric ring by a flexible region containing a ß-stalk and a helical bundle (DII internal). Each RUVBL1 and RUVBL2 subunit contains a nucleotide-binding pocket and the adjacent subunit in the hexamer provides the arginine finger motif required for hydrolysis. Several structures of RUVBL1-RUVBL2 complexes reveal that nucleotides are present in the complex even if they were not supplemented during purification (Gorynia et al., 2011; Lakomek et al., 2015; Matias et al., 2006; Muñoz-Hernández et al., 2019).

Figure 1. RUVBL1-RUVBL2 interacts with DHX34.

(A) Top panels: Schematic representation of RUVBL1 (blue) and RUVBL2 (pink) domains and catalytic motifs. Bottom panel: structure of the human RUVBL1-RUVBL2 hetero-hexameric ring with protruding domain II (DII), generated from atomic structures of RUVBL1 (PDB 2C9O) and RUVBL2 (PDB 6H7X) (Matias et al., 2006; Silva et al., 2018). Top and bottom views are shown with the color code from top panel. The ATPase-face and DII-face of the ring as well as the internal and external regions of DIIs are indicated. (B) Pull-down experiment testing the interaction of purified His-RUVBL1-RUVBL2 with DHX34, using His-tag affinity purification. Proteins bound to affinity beads were eluted and analyzed by SDS-PAGE and stained using Oriole Fluorescent Gel Stain (Bio-Rad). DHX34 was found to elute specifically only when His-RUVBL1-RUVBL2 was present. (C, D) Immunoprecipitation (IP) of transiently transfected HEK293T cells with T7-DHX34 from HEK293T cells was performed in the presence of RNase A. Inputs (0.5%) and anti-FLAG-IPs (20%) were subjected to western analysis using the indicated antibodies. Proteins bound to T7 tag affinity beads were eluted and analyzed by SDS-PAGE and western blot using antibodies against the T7 tag in DHX34 and RUVBL1 (C) or RUVBL2 (D). For Inputs (0.5%) and anti-T7 IP (20%) are shown. (E) IP experiment testing the interaction of FLAG-RUVBL1 and HA-RUVBL2 co-expressed in HEK293T cells with T7-DHX34. Inputs (0.5%) and anti-FLAG-IPs (20%) were analyzed by SDS-PAGE and western blot using antibodies against DHX34, RUVBL1 and RUVBL2. These antibodies detected both transfected and endogenous proteins and are indicated on the left site of the panel.

Figure 1.

Figure 1—figure supplement 1. Testing the interaction between RUVBL1-RUVBL2 and NMD factors.

Figure 1—figure supplement 1.

(A) Representative 2D averages of purified His-RUVBL1-RUVBL2 analyzed by cryo-EM. Scale bar, 10 nm. Features of the RUVBL1-RUVBL2 complex are indicated. (B) Pull-down experiment testing the interaction of purified His-RUVBL1-RUVBL2 with UPF1115-914, UPF2, UPF3b, and EJC using His-tag affinity purification. Proteins bound to affinity beads were eluted and analyzed by SDS-PAGE and stained using Quick Coomassie (Generon). None of these proteins interacted with RUVBL1-RUVBL2. Some elution detected for UPF2 (lane 14) corresponded to background binding by the beads since a similar elution was observed in the control experiment lacking His-RUVBL1-RUVBL2 (lane 10). (C) Immunoprecipitation assay testing the interaction of UPF1 and UPF2 with RUVBL1 and RUVBL2 using overexpressed FLAG-UPF1 and FLAG-UPF2 in cell extracts. Pulldowns show no increased signal for RUVBL1 and RUVBL2 compared to the negative control. (D) Immunoprecipitation experiment testing the interaction of endogenous UPF1 and UPF2 with RUVBL1 and RUVBL2 from cell extracts, using antibodies against endogenous UPF1 and UPF2. This experiment suggests that RUVBL1 and RUVBL2 do not interact with UPF1 or UPF2. Together with the lack of direct interaction detected in ‘C’ and when using purified proteins in ‘B’, these experiments were interpreted as indicating a lack of interaction between RUVBL1-RUVBL2 and either UPF1 or UPF2. (E) 4–15% SDS-PAGE showing a Ni-NTA agarose resin pull-down experiment of His-RUVBL1-RUVBL2 incubated with FLAG-SMG1-SMG8-SMG9 (FLAG-SMG1-8-9), stained with Oriole Fluorescent Gel Stain (Bio-Rad). Lanes 1 and 3 correspond to the input and elution of an experiment containing only FLAG-SMG1-SMG8-SMG9. Lanes 2 and 4 correspond to the input and elution of an experiment containing FLAG-SMG1-SMG8-SMG9 incubated with His-RUVBL1-RUVBL2. (F) SDS-PAGE of pull-down experiment as in (B) but using the FLAG tag in SMG1 as bait. Lanes 1 and 3 correspond to the input and elution of an experiment containing FLAG-SMG1-SMG8-SMG9 and His-RUVBL1-RUVBL2. Lanes 2 and 4 corresponds to input and elution of an experiment containing only His-RUVBL1-RUVBL2. (G) 4–15% SDS-PAGE and Quick Coomassie (Generon) staining of purified DHX34 constructs used: wild-type (wt) DHX34 and the DHX34 mutant lacking the CTD domain (ΔCTD) used in Figure 4—figure supplement 1D.

RUVBL1 and RUVBL2 are essential constituents of several large complexes. In various chromatin-remodeling complexes such as INO80 and SRCAP, these ATPases form a scaffold that organizes the architecture of other subunits in the complex (Aramayo et al., 2018; Eustermann et al., 2018; Feng et al., 2018). RUVBL1 and RUVBL2 also interact with RPAP3 and PIH1D1 proteins to form the R2TP complex, a HSP90 co-chaperone involved in the assembly and maturation of some large complexes including RNA polymerase II and members of the Phosphatidylinositol 3-kinase-related kinase (PIKK) family such as ATR, ATM, SMG1, and mTOR (Houry et al., 2018; Martino et al., 2018; Maurizy et al., 2018; Muñoz-Hernández et al., 2019; Rivera-Calzada et al., 2017). In all these complexes, the DII-face of the RUVBL1-RUVBL2 ring is used as scaffold platform for the interaction with other proteins, which are recruited by the DII domains. One exception is the C-terminal domain of RPAP3 that binds at the ATPase-face of the ring through the interaction with RUVBL2 but not RUVBL1 (Martino et al., 2018; Maurizy et al., 2018; Muñoz-Hernández et al., 2019).

ATP binding or hydrolysis by RUVBL1 and/or RUVBL2 is essential to all the reported activities in cells (Izumi et al., 2010; Rajendra et al., 2014; Venteicher et al., 2008), but the purified proteins display very weak ATPase activity in vitro (Nano et al., 2020; Gorynia et al., 2011). Little is known about the function of RUVBL1-RUVBL2-mediated ATP hydrolysis or how this is regulated within the cell. Inhibition of the RUVBL1-RUVBL2 ATPase stabilizes interactions with clients and proteins involved in mTOR assembly in cells (Yenerall et al., 2020). This and the low rates of ATP hydrolysis indicates that RUVBL1-RUVBL2 might not function as a processive ATPase but rather as a switch regulated through interacting partners. Recent structures suggest that the interaction of proteins with the DII domains can alter the conformation of the RUVBL1-RUVBL2 hexameric ring. PIH1D1 in the R2TP complex and the insertion domain of Ino80 in the INO80 complex interact with the DII domains, inducing conformational changes in regions of the ATPase ring (Aramayo et al., 2018; Muñoz-Hernández et al., 2019). In the R2TP complex, the interaction of PIH1D1 also induces changes in a region at the N-terminus of one RUVBL2 subunit that contains two histidine residues (His25 and His27) that contribute to the interaction with the nucleotide. However, it has not been demonstrated whether these changes could regulate the ATPase activity of RUVBL1-RUVBL2.

In addition to their role as components of some macromolecular complexes, RUVBL1 and RUVBL2 regulate several cellular processes, including the Fanconia Anemia (FA) pathway, the assembly of the telomerase holoenzyme, and nonsense-mediated mRNA decay (NMD), a mechanism that removes aberrant transcripts. In FA, RUVBL1 and RUVBL2 associate with some components of the pathway, and their depletion reduces the amount of the FA core complex (Rajendra et al., 2014). Interestingly, monoubiquitination of FANCD2 and FANCI, a measure of the activation of the FA pathway, can be rescued by siRNA-resistant versions of RUVBL1 but not by an ATPase-dead mutant. The assembly of the human telomerase holoenzyme also requires RUVBL1 and RUVBL2 and the levels of assembled telomerase in RUVBL1-depleted cells can be rescued by the expression of the wild-type protein but not by an ATPase-deficient mutant (Venteicher et al., 2008). An ATPase active RUVBL1-RUVBL2 complex is also required for phosphorylation of UPF1 by the SMG1 kinase, one of the key steps to initiate NMD (Izumi et al., 2010). In this work, we focus on the study of RUVBL1 and RUVBL2 ATPases in the context of the NMD pathway.

NMD controls the quality of mRNAs by removing aberrant transcripts containing premature termination codons (PTCs). These are generated as errors during transcription or splicing, but they also appear through germline mutations in a number of genetic disorders (Hug et al., 2016; Kurosaki et al., 2019). NMD also plays an important role in fine-tuning gene expression by regulating the abundance of a significant fraction of physiological transcripts (Nasif et al., 2018), affecting functions such as stem cell differentiation (Lou et al., 2016). NMD is initiated by the assembly of transient multi-subunit complexes containing the up-frameshift (UPF) core NMD factors, UPF1, UPF2, and UPF3b, bound to the target mRNA (Hug et al., 2016; Kurosaki et al., 2019). First, the RNA helicase UPF1 and its specific kinase SMG1 bind to eukaryotic release factors eRF1 and eRF3 at ribosomes stalled at a PTC, forming the so-called surveillance (SURF) complex, where SMG1 is inhibited by the interaction of SMG8 and SMG9, two factors that block the access to the kinase domain (Gat et al., 2019; Melero et al., 2014; Zhu et al., 2019). Remodeling of the SURF complex by the interaction with NMD core factors UPF2 and UPF3b bound to the Exon Junction Complex (EJC) leads to the phosphorylation of UPF1 by SMG1, which results in the recruitment of factors that promote mRNA degradation. A fully functional NMD response requires the contribution of several other proteins beyond the core NMD machinery, including DHX34 (DEAH box protein 34), a DEAH box family RNA helicase that is required to initiate NMD (Hug and Cáceres, 2014; Longman et al., 2007). DHX34 is made of a structural core containing two canonical recombinase A (RecA)-like domains, a winged-helix domain (WH), a helical bundle (the Ratchet domain), and an OB-fold domain, followed by a short C-terminal domain (CTD) (Hug and Cáceres, 2014; Melero et al., 2016). DHX34 promotes UPF1 phosphorylation and although the mechanism is unknown, current evidence suggests this occurring in complex with the SMG1 kinase and its substrate UPF1. A region around the RecA domains in DHX34 binds UPF1 directly, whereas the CTD interacts with SMG1 (Hug and Cáceres, 2014; Melero et al., 2016). DHX34 variants lacking the CTD domain fail to promote the degradation of a PTC-containing NMD reporter (Melero et al., 2016). Only recently, germline pathogenic variants of DHX34 were found in four families as specific to familiar forms of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (Rio-Machin et al., 2020). Interestingly, the four variants reduced the recruitment of UPF2 and UPF3b to UPF1, resulting in reduced UPF1 phosphorylation, suggesting a link between DHX34, the NMD pathway and the etiology of some inherited forms of these myeloid malignances.

RUVBL1 and RUVBL2 are also potential new non-canonical NMD regulators. Knockdown of RUVBL1 or RUVBL2 reduces SMG1-mediated UPF1 phosphorylation and affects the degradation of a PTC-containing β-globin reporter. These defects could only be recovered with wild-type and not ATPase-dead mutant versions of RUVBL1 indicating that the ATPase activity of the RUVBL1-RUVBL2 complex is required to initiate the NMD response (Izumi et al., 2010). How RUVBL1 and RUVBL2 participate in NMD and how their ATPase activity is regulated in this pathway remains enigmatic.

Here, we demonstrate that RUVBL1-RUVBL2 hetero-hexamers can bind directly to DHX34 in vitro and in cells in culture. Cryo-electron microscopy (cryo-EM) reveals that DHX34 induces global conformational changes in the RUVBL1-RUVBL2 complex with the RUVBL2 subunit being mostly affected. DHX34 destabilizes the N-termini of all RUVBL2 subunits and in consequence ATP hydrolysis activity by RUVBL2 is reduced. This demonstrates that interacting partners can profoundly affect the structure and activity of RUVBL1-RUVBL2 hetero-hexameric complexes. Our results suggest that DHX34 could couple the regulation of RUVBL1-RUVBL2 ATPase activity to the assembly of the complexes that initiate the NMD response.

Results

RUVBL1-RUVBL2 and DHX34 form a complex in vitro and in cells

To uncover the function of RUVBL1 and RUVBL2 in NMD, we sought to address whether these AAA-ATPases can interact directly with some of the core protein factors involved in the initiation of NMD. Pull-down experiments from cell extracts cannot easily differentiate direct interactions from those associations that are mediated by connecting partners. Thus, we first tested which NMD factors could bind directly to RUVBL1-RUVBL2 using purified proteins and in vitro interaction assays, and subsequently verified them in cell lysates.

For this, RUVBL1 and RUVBL2 were co-expressed and purified as heteromeric complexes containing His-RUVBL1 and RUVBL2 in equimolar amounts, and forming oligomeric complexes where two hexameric rings interact though the DII domains, as revealed by cryo-EM (Figure 1—figure supplement 1A), and in agreement with what we described before (López-Perrote et al., 2012; Martino et al., 2018). We first tested the interaction between RUVBL1-RUVBL2 complexes and UPF1115-914 (a truncated version lacking the flexible N- and C-terminal ends of UPF1), UPF2, UPF3b, EJC, and DHX34 by pull-down experiments using the His-tag in RUVBL1 (Figure 1B, Figure 1—figure supplement 1B–D). Of all these, only DHX34 interacted directly with RUVBL1-RUVBL2 forming a stable complex that has not been previously described. We then verified the in vitro results using immunoprecipitation experiments from cells. When DHX34 was pulled down from cells, both RUVBL1 and RUVBL2 were detected by western blot (Figure 1C–D). The interaction between DHX34, RUVBL1 and RUVBL2 in cell lysates was further confirmed in immunoprecipitation experiments using FLAG-RUVBL1 (Figure 1E). FLAG-RUVBL1 eluted also endogenous RUVBL1 and RUVBL2, in agreement with the oligomeric nature of the complexes formed by these ATPases. Together, these results reveal a direct interaction between RUVBL1 and RUVBL2 and DHX34.

We also analyzed the interaction with SMG1, the kinase that phosphorylates UPF1, since this is the key event triggering NMD and RUVBL1-RUVBL2 has been found in complexes containing SMG1 in cell extracts (Izumi et al., 2010). SMG1 was purified by affinity chromatography in complex with SMG8 and SMG9 and incubated with His-RUVBL1-RUVBL2. A pull-down experiment using the His-tag in RUVBL1 revealed that SMG1 forms a direct complex with RUVBL1-RUVBL2 and similar results were obtained in pull-down experiments using a FLAG-tag in SMG1 as bait. Curiously, in both types of experiments, SMG1 and RUVBL1-RUVBL2 interact but SMG8 and SMG9 were undetected in the elution, suggesting that the formation of a complex between RUVBL1-RUVBL2 and SMG1 exclude SMG8 and SMG9 (Figure 1—figure supplement 1E–F).

Together, these results indicate that RUVBL1-RUVBL2 can interact directly with the NMD factors SMG1 and DHX34. In this work, we focused on the characterization of how DHX34 binds to RUVBL1-RUVBL2 and the consequences of this interaction.

Cryo-EM of the RUVBL1-RUVBL2-DHX34 complex

To gain deeper insight into the consequences of the interaction of DHX34 with RUVBL1 and RUVBL2, we purified the RUVBL1-RUVBL2-DHX34 complex for structural characterization. The purification was optimized so that yields and homogeneity of the complex were suitable for structural studies (Figure 2A). For this, we coupled the purification of DHX34 from HEK293 cells with its binding to RUVBL1-RUVBL2. FLAG-DHX34 from cell extracts was bound to an immunoaffinity anti-FLAG resin and the beads were washed and incubated with purified RUVBL1-RUVBL2 prior to elution. Next, we used cryo-EM to determine the structure of the RUVBL1-RUVBL2-DHX34 complex. Freshly purified RUVBL1-RUVBL2-DHX34 was applied to holey-carbon grids, vitrified and cryo-EM images were collected.

Figure 2. Cryo-EM of the RUVBL1-RUVBL2-DHX34 complex.

(A) Purified RUVBL1-RUVBL2-DHX34 complex used for structural studies in a 4–15% SDS-PAGE stained with Quick Coomassie (Generon). (B) Representative reference-free 2D averages from cryo-EM images of the complex. Side views clearly show the projection of one ring with some density attached to the DII face (close-up right panel). Scale bar represents 10 nm. (C) Several views of the cryo-EM density obtained for RUVBL1-RUVBL2-DHX34 (RUVBL1 in blue, RUVBL2 in pink, and DHX34 in gray). ATPase core and DII domains in RUVBL1-RUVBL2 are indicated. Scale bar represents 25 Å.

Figure 2.

Figure 2—figure supplement 1. Image processing of the cryo-EM images of the RUVBL1-RUVBL2-DHX34 complex workflow of the image processing strategy followed in this work.

Figure 2—figure supplement 1.

After some initial steps of image ‘cleaning’ and classification, a consensus refinement for 83.8% of the particles was obtained. From these initial stages, image processing was divided in two branches. To resolve the structure of the RUVBL1-RUVBL2 without the effect of DHX34 and the OB-fold domains, we removed the influence of the density of these flexible regions by using a mask, and refinements and classifications were focused only in the ring. In parallel, we refined the structure of the full complex. For this, particles were first classified according to the quality of the DHX34 density, removing those particles were the density was too small to accommodate DHX34. Then, these particles were classified and refined using the information of the whole complex. Scale bar represents 25 Å.
Figure 2—figure supplement 2. Resolution estimation of the cryo-EM for the RUVBL1-RUVBL2-DHX34 complex.

Figure 2—figure supplement 2.

(A) Fourier Shell Correlation (FSC) curves estimating the average resolution of the cryo-EM volume of the RUVBL1-RUVBL2-DHX34 complex after refinement using the gold standard defined in RELION-3 (Zivanov et al., 2018). (B) Local resolution estimates map of RUVBL1-RUVBL2-DHX34 complex as provided by RELION. Bottom and side views of the complex are shown using the color scale shown on the right. Scale bar, 25 Å.
Figure 2—video 1. Cryo-EM structure of the RUVBL1-RUVBL2-DHX34 complex.
Download video file (21.4MB, mp4)
Several views of the cryo-EM density of the RUVBL1-RUVBL2-DHX34 complex, colored as in Figure 2.

2D averages of RUVBL1-RUVBL2-DHX34 revealed hexameric RUVBL1-RUVBL2 complexes with putative density for DHX34 located at the DII-face of the ring. The interaction of DHX34 disrupts the RUVBL1-RUVBL2 dodecameric double-ring complexes, an effect observed before in the assembly of R2TP (Martino et al., 2018; Muñoz-Hernández et al., 2019; Figure 2B). An extensive 2D and 3D classification strategy of the images revealed that DHX34 attaches to the DII-face of the RUVBL1-RUVBL2 ring flexibly and we selected the most homogenous sub-group of particles for refinement (Figure 2—figure supplement 1, Table 1). The structure of RUVBL1-RUVBL2-DHX34 was determined at an average resolution of 5.0 Å (Figure 2—figure supplement 2A), with local resolutions up to 4.1 Å for the core RUVBL1-RUVBL2 whereas the resolution of DHX34 in the complex was around 8–10 Å (Figure 2—figure supplement 2BFigure 2—video 1). The disparity in resolution between DHX34 and RUVBL1-RUVBL2 in the complex was a strong indication of the flexible attachment of DHX34 to the ATPases. Thus, the cryo-EM density for DHX34 could represent an average of several conformations if the hexameric RUVBL1-RUVBL2 directs alignment during image processing. Local resolution estimation for the OB folds in the DII domains of RUVBL1-RUVBL2 showed a similar resolution distribution (8–10 Å) due to their intrinsic flexibility (Figure 2—figure supplement 2B; Martino et al., 2018).

Table 1. Cryo-EM data collection and parameters.

Data collection and processing
Structure RUVBL1-RUVBL2-DHX34
(EMD-11788)
RUVBL1-RUVBL2 ATPase core
(EMD-11789)
(PDB ID 7AHO)
Microscope FEI Titan Krios FEI Titan Krios
Detector Gatan K2 (counting mode) Gatan K2 (counting mode)
Magnification 47756 47756
Voltage (kV) 300 300
Electron exposure (e–/Å2) 48.1 (40 fractions) 48.1 (40 fractions)
Defocus range (μm) −1.5 to −3.0 −1.5 to −3.0
Pixel size (Å) 1.047 1.047
Symmetry imposed C1 C1
Initial particle images (no.) 353 057 353 057
Final particle images (no.) 41237 101774
Map resolution (Å)
FSC threshold
4.97
0.143
4.18
0.143
Map resolution range (Å) 4.0–12.0 3.8–6.0

DHX34 binds to the internal regions of the DII domains in the hetero-hexameric RUVBL1-RUVBL2 ring. The DII external domains (OB-folds) are mostly free and potentially accessible for interaction with other partners (Figure 2C). DHX34 contacts several RUVBL1 and RUVBL2 subunits of the complex, thus inducing global conformational changes in the structure of the ATPases (see below).

DHX34 induces conformational changes in the N-termini of RUVBL2

We first analyzed the structure of the RUVBL1-RUVBL2 ring using a mask that removed the influence of DHX34 and the protruding OB-fold domains during image processing (Figure 2—figure supplement 1). This way the average resolution of RUVBL1-RUVBL2 improved to 4.2 Å (Figure 3A, Figure 3—figure supplement 1A,B, Table 1) detecting the presence or absence of nucleotide in the nucleotide-binding pockets of both subunits (Figure 3—figure supplement 1C,D). The resolution was sufficient to model the structure of the RUVBL1-RUVBL2 ring after its interaction with DHX34 with the help of the crystal structure of RUVBL1-RUVBL2 (PDB 2XSZ) (Figure 3—figure supplement 2A–C, Tables 23).

Figure 3. DHX34 induces large conformational changes in RUVBL2.

(A) Side and bottom views of the RUVBL1-RUVBL2 ring obtained after refinement without the influence of DHX34 and the OB-fold domains. Squares highlight N-terminal segments of RUVBL1 (blue) and RUVBL2 (pink). Scale bar represents 25 Å. The presence and absence of RUVBL1 and RUVBL2 N-terminal regions is indicated only in one copy of each subunit, but it applied to all the subunits in the complex. (B) Bottom view of the atomic structure of RUVBL1-RUVBL2 ring modeled from the cryo-EM density. Color codes are as in (A). (C) Right panel: a view of the nucleotide binding region in RUVBL2 from the crystal structure of RUVBL1-RUVBL2 (PDB 2SXZ) in gray color; left panel: similar view of RUVBL2 in RUVBL1-RUVBL2 after DHX34 binding (this work, pink). (D) Close-up view of the nucleotide-binding regions in RUVBL1, comparing the structure after DHX34 binding (left panel) and the crystal structure of the RUVBL1-RUVBL2 complex (PDB 2SXZ) (right panel) in gray. N-terminal histidines (H18 and H20) are indicated in gray, Walker A residues in orange, Walker B in red, and the Arg finger in yellow. (E) As in (D) but for the RUVBL2 subunit. Color codes for relevant and catalytic motifs are represented as in (D).

Figure 3.

Figure 3—figure supplement 1. Resolution estimation of the cryo-EM for RUVBL1-RUVBL2 after DHX34 binding.

Figure 3—figure supplement 1.

(A) Fourier Shell Correlation (FSC) curves for the hexameric ring after refinement removing the influence of DHX34 and the OB-fold domains. (B) Local resolution estimates for the hexameric ring of RUVBL1-RUVBL2 as provided by RELION. Bottom and side views of the map are shown using the color scale shown on the right. Scale bar, 25 Å. (C) Close-up of the local resolution estimates centered in the nucleotide binding pockets of RUVBL1, showing all three subunits. Top panels show the density of the local resolution map using the same color code as in (B). Bottom panels show the same region but as a mesh with the atomic model fitted. (D) As ‘C’, but for each RUVBL2 subunit.
Figure 3—figure supplement 2. High-resolution features in cryo-EM map.

Figure 3—figure supplement 2.

(A) Fourier Shell Correlation (FSC) curves for the atomic model versus the cryo-EM density of the RUVBL1-RUVBL2 ATPase core using for modeling. (B) Close-up views of RUVBL1 (left) and RUVBL2 (right) internal DII domains superimposed with the structure of unliganded RUVBL1-RUVBL2 (PDB 2SXZ) in gray color. (C) Selected areas showing high-resolution features with side chain of some residues shown. Scale bar, 5 Å.
Figure 3—figure supplement 3. Analysis of conformational changes in each RUVBL2 subunit.

Figure 3—figure supplement 3.

Experiment 1. RUVBL1-RUVBL2-DHX34 particles were classified in six groups with a mask that removed the influence of DHX34 and the flexible DII domains from the analysis. Each sub-group was analyzed by fitting the atomic structure of the RUVBL1-RUVBL2 core domains (PDB 2XSZ). Cryo-EM density for RUVBL1-RUVBL2 is shown as a white transparency, RUVBL1 is shown in blue color and RUVBL2 in pink color. The percentage of particles in each subgroup is indicated. All groups showed density for the N-termini of RUVBL1. The N-termini of RUVBL2 present in the crystal structure is not present in the cryo-EM density of any subunit in any of the groups. The positions of the N-termini of RUVBL2 are indicated with asterisks.
Figure 3—figure supplement 4. Analysis of conformational changes in each RUVBL2 subunit.

Figure 3—figure supplement 4.

Experiment 2. RUVBL1-RUVBL2-DHX34 particles were classified in six groups with a mask centered in only one RUVBL1-RUVBL2 dimer at a time. Each sub-group was analyzed by fitting the atomic structure of the RUVBL1-RUVBL2 core domains (PDB 2XSZ). Cryo-EM density for RUVBL1-RUVBL2 is shown as a white transparency, RUVBL1 is shown in blue color and RUVBL2 in pink color. The percentage of particles in each subgroup is indicated. All groups showed density for the N-termini of RUVBL1. The N-termini of RUVBL2 present in the crystal structure is not present in the cryo-EM density of any subunit in any of the groups. The positions of the N-termini of RUVBL2 are indicated with asterisks.
Figure 3—figure supplement 5. Analysis of conformational changes in each RUVBL2 subunit.

Figure 3—figure supplement 5.

Experiment 3. The conformation of each RUVBL1-RUVBL2 dimer was analyzed using a symmetry expansion strategy. Each particle was rotated twice along its longitudinal axis so that each of the three RUVBL1-RUVBL2 dimers in each particle locates in the same position. After the expansion the data set is triplicated. Then, particles were locally classified in six groups using a mask focused in only one dimer. Each sub-group was analyzed by fitting the atomic structure of the RUVBL1-RUVBL2 core domains (PDB 2XSZ). Cryo-EM density for RUVBL1-RUVBL2 is shown as a white transparency, RUVBL1 is shown in blue color and RUVBL2 in pink color. The percentage of particles in each subgroup is indicated. All groups showed density for the N-termini of RUVBL1. The N-termini of RUVBL2 present in the crystal structure is not present in the cryo-EM density of any subunit in any of the groups. The positions of the N-termini of RUVBL2 are indicated with asterisks. A small percentage of particles (2.1%) showed a partial loss of density for RUVBL2 N-termini, which can be due in most part to the lower resolution of this subset.

Table 2. Validation statistics for the atomic model of RUVBL1-RUVBL2 ATPase core.

Refinement RUVBL1-RUVBL2 ATPase core
Software phenix.real_space_refine
Coot
Initial model used (PDB code) 2XSZ
Model resolution (Å) 4.1
FSC threshold 0.5
Map sharpening B factor (Å2) −222.98
Model composition 13521
Non-hydrogen atoms 1748
Model composition
Non-hydrogen atoms 13521
Protein residues 1748
Ligands ADP (3)
R.m.s. deviations
Bond lengths (Å) 0.006
Bond angles (°) 0.911
Validation
MolProbity score 1.70
Clashscore 6.95
Poor rotamers (%)
Ramachandran plot (%)
Favored 95.39
Allowed 4.61
Disallowed 0.00
Rotamer outliers (%) 0.21

Table 3. Correlation Coefficients (CC) of the atomic after model refinement.

Correlation Coefficients (CC) after model refinement of RUVBL1-RUVBL2_core map
CC (mask) 0.77
CC (box) 0.72
CC (peaks) 0.62
CC (volume) 0.76
Mean CC for ligands 0.84

The most striking feature in the cryo-EM map is that the N-terminal regions that contribute to nucleotide binding (Muñoz-Hernández et al., 2019; Silva et al., 2018) are visualized in RUVBL1 but not in any of the three RUVBL2 subunits (Figure 3A,B). We performed several experiments to fully verify that every RUVBL2 in the complex lacked density for the N-terminal region. We first searched for heterogeneity in RUVBL1-RUVBL2 by classifying the images of the ring in several 3D subgroups using a mask and we did not find sub-populations of particles where the N-terminal region of RUVBL2 was visible (Figure 3—figure supplement 3). Next, we classified every position of RUVBL1-RUVBL2 dimers in six subclasses to search for heterogeneities within each position (Figure 3—figure supplement 4). More than 70% of particles in every position corresponded to particles clearly missing density of RUVBL2 N-terminus. Density for the N-terminus was not well defined for a small fraction of particles, but these corresponded to low-resolution structures due to the small number of images in these sub-groups. Finally, we applied a symmetry expansion strategy as described before (Martino et al., 2018). For this, we rotated each particle around the 3-fold symmetry axis three times (0°, 120°, and 240°) to place all RUVBL1-RUVBL2 dimers in the same position, thus triplicating the data set. Next, by placing a mask around one position now containing all existing RUVBL1-RUVBL2 dimers, we subjected the symmetry-expanded data to classification, searching for heterogeneity in all the available RUVBL1-RUVBL2 dimers regardless of its position in the ring (Figure 3—figure supplement 5). This analysis further confirmed that all dimers lack the RUVBL2 N-terminal regions. Based on these observations, we conclude that DHX34 induce changes that affect the conformation of RUVBL2 N-terminal regions in all three subunits of the complex.

DHX34 induces the loss of nucleotide in every RUVBL2 subunit

The conformational changes in the N-terminus of RUVBL2 were coupled to the loss of nucleotide (Figure 3C). We and others have observed that RUVBL1-RUVBL2 co-purifies with nucleotides bound to all six subunits (Gorynia et al., 2011; Lakomek et al., 2015; Matias et al., 2006; Muñoz-Hernández et al., 2019), but whereas nucleotide remains bound to RUVBL1 in the RUVBL1-RUVBL2-DHX34 complex (Figure 3D), this is lost in all three RUVBL2 subunits (Figure 3E). The absence of density for nucleotide in RUVBL2 could not be attributed to a lack of sufficient resolution because nucleotides are clearly present in all RUVBL1 subunits in the same complex at similar resolution (Figure 3—figure supplement 1C,D).

DHX34 induces conformational changes in other regions of RUVBL1 and RUVBL2 besides the N-termini of RUVBL2 (Figure 3—figure supplement 2BVideo 1). These changes affect mostly to the internal regions of the DII domains and regions in the AAA-ring. These changes do not affect key residues of the RUVBL1 nucleotide-binding pocket, which explains why ADP remains bound to RUVBL1 after the interaction with DHX34 (Figure 3D). The structure of the nucleotide-binding pocket in RUVBL2 is not altered significantly with respect to the crystal structure of RUVBL2 bound to nucleotide (Figure 3E). This suggests that it is the displacement of the N-termini of RUVBL2 that is mostly responsible for the loss of nucleotide. Together, our results reveal that DHX34 affects nucleotide binding of every RUVBL2 subunit in the complex by stabilizing a conformation that displaces the N-termini of RUVBL2.

Video 1. Atomic structure of the RUVBL1-RUVBL2 ATPase ring.

Download video file (35.6MB, mp4)

Several views of the atomic model for RUVBL1-RUVBL2 to show the conformational changes in the hexameric ring after the interaction with DHX34. During the video, the structure is superimposed to the atomic structure of the RUVBL1-RUVBL2 ATPase ring (PDB 2SXZ) in gray color, to highlight the differences in RUVBL2 and RUVBL1, and the loss of nucleotide in RUVBL2. In the final part of the video, the morphing between the crystal structure of the RUVBL1-RUVBL2 ATPase ring (PDB 2SXZ) and the structure described is this work highlights the conformational changes induced by DHX34 in the polypeptide chains. During morphing, nucleotides in both subunits and both conformations have been removed, as well as the N-terminal region of RUVBL2, which is only present in the crystal structure and it cannot be modeled in the DHX34-bound structure.

DHX34 makes multiple contacts through different domains with RUVBL1-RUVBL2

Next, we focused on the analysis of the structure of DHX34, whose resolution was lower than that of the RUVBL1-RUVBL2 hexameric ring. In an attempt to improve the resolution of DHX34, we extracted the density corresponding to the protein in each particle by applying density subtraction methods. These images were processed and classified without the influence of RUVBL1-RUVBL2 (Figure 4—figure supplement 1A,B). Despite our efforts, we were unable to improve the structure of DHX34. We suspect this could be a consequence of the limited number of images since small proteins need large datasets that allow classification and identification of the best particles in a homogenous conformation. This also indicates that the density of DHX34 of the cryo-EM map resolved in the context of the full RUVBL1-RUVBL2-DHX34 complex could be affected by the alignment of the AAA ring.

In isolation and at low resolution using negative-stain electron microscopy methods, DHX34 appears as a globular and compact protein comprising all of the conserved core domains, attached to a protruding extension corresponding to the C-terminal domain (CTD) (Melero et al., 2016; Figure 4—figure supplement 1C). The CTD domains appears thicker in the volume of DHX34 than in the electron microscopy images used to obtain the low-resolution structure due to its flexibility and the use of staining agents (Melero et al., 2016). We compared the cryo-EM volume of DHX34 extracted from the RUVBL1-RUVBL2-DHX34 complex with the low-resolution map of isolated DHX34. This comparison revealed that the dimensions of the DHX34 density that we observe attached to one ring of RUVBL1-RUVBL2 can only agree with one copy of DHX34, and that possibly, it is the DHX34 core domains and not the CTD that interact with RUVBL1-RUVBL2. Accordingly, purified DHX34 can still bind RUVBL1-RUVBL2 when its flexible C-terminal domain has been deleted (Figure 4—figure supplement 1D). In addition, we estimated that the approximate mass of the volume occupied by DHX34 in the complex with RUVBL1-RUVBL2 is around 120 kDa by using the volume programme in EMAN (Ludtke et al., 1999) (https://blake.bcm.edu/emanwiki/Volume). This tool estimates the mass enclosed by an isosurface using an average density for proteins of 1.35 g/ml (0.81 Da/A3). Monomeric DHX34 and the DHX34 core domains alone have a molecular mass of 132 kDa and 111 kDa, respectively. Together, these analyses strongly suggest that one copy DHX34 interacts with one RUVBL1-RUVBL2 hexamer forming a complex with 3:3:1 stoichiometry.

Next, we tested whether any individual domain of DHX34 could have a significant role in mediating the interactions with RUVBL1-RUVBL2 in cultured cells. For this, we analyzed several DHX34 mutants (Figure 4A). We first tested a series of systematic domain deletion mutants and found that all single domain deletions retained binding to RUVBL1 and RUVBL2 to a measurable degree (Figure 4B). In order to test the importance of several DHX34 domains for RUVBL1 and RUVBL2 binding, we next analyzed larger truncated versions of DHX34 (Figure 4C). As shown by the quantification in Figure 4D, no domain is sufficient and necessary on its own to mediate the interaction with RUVBL1-RUVBL2. Heavily N- and C- terminal truncated versions of DHX34 showed a pronounced reduction in binding to RUVBL1-RUVBL2 but they could still bind to the ATPases (Figure 4D). Overall this analysis indicated that several interactions through different domains are made between DHX34 and RUVBL1-RUVBL2, which agrees with the structure of the complex that shows multiple regions of contact between DHX34 and the ATPases.

Figure 4. Mapping the interaction between DHX34 and RUVBL1-RUVBL2 in cells.

(A) Cartoon depicting the functional domains of DHX34, showing the residue numbers that define their boundaries. Names of the domains are: N-terminal (NTD), L, RecA1, RecA2, winged-helix (WH), Ratchet, OB-fold and C-terminal (CTD). (B–C) Effect of domain deletions of DHX34 (B) and larger truncation including several domains (C) on the interaction with RUVBL1 and RUVBL2 using cell extracts. The Immunoprecipitation (IP) of T7-tagged versions of DHX34 was analyzed by western blot using antibodies against the T7 tag, RUVBL1 and RUVBL2. (D) Quantification of the experiments shown in ‘B’ and ‘C’. The protein levels in the IP were quantified and normalized to the levels in the Input. Binding is expressed as IP enrichment compared to the empty vector control (-). For each expressed polypeptide, at least two independent experiments were analyzed.

Figure 4.

Figure 4—figure supplement 1. Analysis of the images of DHX34 in complex with RUVBL1-RUVBL2.

Figure 4—figure supplement 1.

(A) Workflow for the image processing of DHX34 extracted from the images of the RUVBL1-RUVBL2-DHX34 complex. Scale bar, 25 Å. (B) Fourier Shell Correlation (FSC) curves for the DHX34 structure after refinement removing the influence of RUVBL1-RUVBL2 ring using density subtraction protocols. (C) Comparison between the structure of isolated DHX34 (Melero et al., 2014) and the DHX34 in complex with RUVBL1-RUVBL2 resolved at low-resolution structure. Left panel, structure of isolated DHX34 as a solid density (Melero et al., 2014). Right panel, structure of isolated DHX34 as mesh fitted with the low-resolution DHX34 from this work. Scale bar, 25 Å. (D) Effect of the truncation of the C-terminal domain (CTD) of DHX34 in the formation of a complex with RUVBL1-RUVBL2. The experiment was performed by pull-down of the His-tag in RUVBL1 in RUVBL1-RUVBL2 after incubation with DHX34-ΔCTD using purified proteins. SDS-PAGE was stained using Oriole Fluorescent Gel Stain (Bio-Rad).

DHX34 down-regulates RUVBL2 ATPase activity

We analyzed if the conformational changes induced by DHX34 correlate with changes in the ATPase activity of the His-RUVBL1-RUVBL2 complex (Figure 5). For these experiments, we expressed and purified the ATP-hydrolysis deficient His-RUVBL1E303Q-RUVBL2E300Q mutant (Gorynia et al., 2011; Lakomek et al., 2015; Matias et al., 2006). We investigated whether these mutations affect the oligomerization of the complex using electron microscopy (Figure 5—figure supplement 1A). We found that His-RUVBL1E303Q-RUVBL2E300Q forms similar oligomers to the wild-type complex and, in addition, it behaves similarly to His-RUVBL1-RUVBL2 when their intrinsic fluorescence was measured using a thermal denaturation assay (Figure 5—figure supplement 1B). In addition, we purified His-RUVBL1E303Q-RUVBL2 and His-RUVBL1-RUVBL2E300Q containing the mutation in either RUVBL1 or RUVBL2. We also purified ATP-hydrolysis-dead mutant (DHX34D279A) to remove the effects of ATP hydrolysis by DHX34 in our experiments (Hug and Cáceres, 2014). DHX34D279A showed an ATP consumption of 24.2% compared with wild-type (Figure 5—figure supplement 1C–E). We also monitored DHX34 stability when incubated at 37°C, measured as changes in the intrinsic fluorescence during a thermal ramp. We found that DHX34 is not affected by 20 min incubation time but it is by 40 min when compared to freshly purified DHX34 (Figure 5—figure supplement 1F). This suggested that the protein might not be stable over long incubation times. Thus, ATPase measurements were restricted to 20 min using fresh preparations for which linearity of ATPase rates were maintained.

Figure 5. DHX34 down-regulates RUVBL2 ATPase activity.

(A) Graph comparing the ATPase activity for His-RUVBL1-RUVBL2, His-RUVBL1E303Q-RUVBL2, His-RUVBL1-RUVBL2E300Q and His-RUVBL1E303Q-RUVBL2E300Q shown as percentage of the rate measured for wild-type RUVBL1-RUVBL2. Standard deviations from three independent experiments are indicated. (B) Graph comparing the ATP activity of His-RUVBL1-RUVBL2 in the presence and absence of DHX34D279A, indicated as percentage of ATPase activity, assuming 100% activity for His-RUVBL1-RUVBL2. Standard deviations from four independent experiments are indicated. Sample His-RUVBL1-RUVBL2 used in these experiments contains a His-tag at the N-terminus of RUVBL1. (C) Graph showing the ATP activity for His-RUVBL1-RUVBL2 complexes where either RUVBL1 or RUVBL2 contains a mutation that abolished ATP hydrolysis (RUVBL1303Q or RUVBL1E300Q) and the effect after incubation with DHX34D279A. In all the experiments the ATPase activity for His-RUVBL1-RUVBL2 shown in ‘B’ is considered as 100%. Standard deviations from three independent experiments are indicated. (D) Model for the regulation of the ATPase activity of RUVBL1-RUVBL2 by DHX34. N-terminal regions in RUVBL1 (blue color) and RUVBL2 (pink color) subunits contribute interactions with the nucleotides in the nucleotide-binding pocket. DHX34 binds to the DII-face of the RUVBL1-RUVBL2 ring and induces large conformational changes in the N-termini of all RUVBL2 subunits promoting the loss of nucleotide and a down-regulation of the ATPase activity. Source files containing the data used for the time course measurements for ATP consumption in Figure 5 and the figure supplement are available in Figure 5—source data 1.

Figure 5—source data 1. Source data for the ATPase activity assays shown in Figure 5, Figure 5—figure supplement 1, Figure 5—figure supplement 2 and Figure 5—figure supplement 3' and the caption to 'The file includes 15 sheets, each one for 1 sample, containing the replicas done for the sample.
In each sheet is included: Name of sample, time (min), absorbance at 340 nm for the replicas, equation of the linear regression trendline for each replica used for data analysis, and R2 value of the linear regression trendline for each replica.

Figure 5.

Figure 5—figure supplement 1. Oligomerization and stability of RUVBL1-RUVBL2 and DHX34 mutants.

Figure 5—figure supplement 1.

(A) The oligomeric state of His-RUVBL1E303Q-RUVBL2E300Q mutant was monitored by using negative stain electron microscopy. His-RUVBL1E303Q-RUVBL2E300Q mutant assembled complexes similar to the wild-type complex when observed in the electron microscope (Figure 1—figure supplement 1). (B) The stability of the His-RUVBL1-RUVBL2 mutants was analyzed using nano-scanning fluorimetry. Graph represents the first derivative of the fluorescence ratios (F350/F330) along the temperature for His-RUVBL1-RUVBL2 (solid line), and His-RUVBL1E303Q-RUVBL2E300Q (dot line). Inflection temperatures (Ti) are indicated on top. (C) 4–15% SDS-PAGE and Quick Coomassie (Generon) staining of purified DHX34D279A. (D) Time course measurements for ATP consumption monitored as absorbance at 340 nm using the pyruvate kinase-lactate dehydrogenase-coupled assay to measure the ATPase activity of DHX34 and ATP-hydrolysis-dead mutant DHX34D279A. (E) Graph comparing the ATP activity in ‘D’ indicated as a percentage of wild-type DHX34. ATP-hydrolysis-dead mutant DHX34D279A mutant shows 24.2% of the ATPase activity measured for wild-type DHX34. Standard deviations from three independent experiments are indicated. (F) The stability of DHX34 after incubation at 37°C was analyzed by nano scanning fluorimetry. These experiments revealed that the protein was not affected after 20 min at 37°C (dot line) but it was significantly affected after 40 min (dashed line), where a second unfolding process is observed at a higher Ti. Source files containing the data used for the time course measurements for ATP consumption in Figure 5 and the figure supplement are available in Figure 5—source data 1.
Figure 5—figure supplement 2. ATPase measurements and time courses for His-RUVBL1-RUVBL2 and several ATPase-dead mutants in the presence and absence of DHX34D279A.

Figure 5—figure supplement 2.

(A) Time course measurements for ATP consumption monitored as absorbance at 340 nm using the pyruvate kinase-lactate dehydrogenase-coupled assay for His-RUVBL1-RUVBL2 (black line) and ATPase-dead mutants of His-RUVBL1E303Q-RUVBL2, His-RUVBL1-RUVBL2E300Q, and His-RUVBL1E303Q-RUVBL2E300Q. (B–D) Time course measurements were performed as in (A) in experiments measuring the ATPase activity of each mutant in the absence or presence of DHX34D279A. Source files containing the data used for the time course measurements for ATP consumption in Figure 5 and the figure supplement are available in Figure 5—source data 1.
Figure 5—figure supplement 3. DHX34D279A interferes with RUVBL1-RUVBL2 ATPase activity also after the His-tag in RUVBL1 was removed.

Figure 5—figure supplement 3.

(A) Time course measurements for ATP activity monitored as absorbance at 340 nm for untagged RUVBL1-RUVBL2 (red line) compared to His-RUVBL1-RUVBL2 (black line). (B) Graph representing the ATPase activity for the experiments in (A) using the values of His-RUVBL1-RUVBL2 as the 100%. (C, D) As in ‘A’ and ‘B’ respectively but after adding DHX34D279A. (E, F) As in ‘A’ and ‘B’ but using two ATPase-dead mutants RUVBL1-RUVBL2E300Q and RUVBL1E303Q-RUVBL2. (G) Graph summarizing the ATPase activity of RUVBL1-RUVBL2 and several mutants in the absence or presence of DHX34D279A. This graph is similar to the one shown in Figure 4 but using untagged RUVBL1-RUVBL2 complex. Source files containing the data used for the time course measurements for ATP consumption in Figure 5 and the figure supplement are available in Figure 5—source data 1.

The ATPase activity of His-RUVBL1-RUVBL2 was determined using a spectrophotometric pyruvate kinase-lactate dehydrogenase-coupled assay that regenerates ATP so that the amount remains constant. The weak ATPase activity of His-RUVBL1-RUVBL2 that we measured at 37°C (4.9 ± 0.8 min−1 of ATP turnover) is similar to what had been determined previously by others (Gorynia et al., 2011; Lakomek et al., 2015; Matias et al., 2006; Figure 5—figure supplement 2A), and this value was set as 100% activity for comparison with subsequent measurements (Figure 5A). We verified that the activity measured corresponded to His-RUVBL1-RUVBL2 using His-RUVBL1E303Q-RUVBL2E300Q (Figure 5A, Figure 5—figure supplement 2A). His-RUVBL1-RUVBL2E300Q and His-RUVBL1E303Q-RUVBL2 complexes that are mutants in only one of the two subunits showed a significant reduction of their ATPase activity as expected if not all the subunits in each oligomer are active (43% and 20% ATPase activity for His-RUVBL1-RUVBL2E300Q and His-RUVBL1E303Q-RUVBL2, respectively, compared to wild-type His-RUVBL1-RUVBL2) (Figure 5A, Figure 5—figure supplement 2A).

We then analyzed the consequences of adding DHX34 (2:1 DHX34:His-RUVBL1-RUVBL2 molar ratio, considering a His-RUVBL1-RUVBL2 hexamer and monomeric DHX34). Interestingly, the ATPase activity was reduced around 50% (2.5 ± 0.9 min−1) (Figure 5B, Figure 5—figure supplement 2B). Most interestingly, adding DHX34 caused no effects in His-RUVBL1-RUVBL2E300Q complexes containing ATPase-dead RUVBL2 subunits (His-RUVBL1-RUVBL2E300Q showed rates of 2.1 ± 0.5 and 2.0 ± 0.5 min−1 in the absence and presence of DHX34D279A, respectively) (Figure 5C, Figure 5—figure supplement 2C). In contrast, ATP hydrolysis by the His-RUVBL1E303Q-RUVBL2 mutant was affected by DHX34 as in the wild-type (His-RUVBL1E303Q-RUVBL2 showed rates of 1.0 ± 0.3 and 0.4 ± 0.1 min−1 in the absence and presence of DHX34D279A, respectively) (Figure 5C, Figure 5—figure supplement 2D). These results are fully in agreement with a model where DHX34 actions on the RUVBL1-RUVBL2 complex are mediated mostly by changes in the RUVBL2 subunits.

Finally, we verified that our results were independent of the presence or absence of the His-tag in RUVBL1 used to purify RUVBL1-RUVBL2. Removal of the tag had a small effect on the rate of ATP hydrolysis of the RUVBL1-RUVBL2 complex (3.6 ± 0.7 min-) (Figure 5—figure supplement 3A,B) but addition of DHX34 caused a similar reduction of ATP hydrolysis (1.0 ± 0.5 min−1), indicating that the presence of the tag does not interfere with the action of DHX34 (Figure 5—figure supplement 3C,D). As in the case of complexes containing His-RUVBL1, DHX34 caused a reduction in the ATPase activity of untagged RUVBL1-RUVBL2 complexes when RUVBL1 was mutated but not when RUVBL2 was mutated (Untagged RUVBL1-RUVBL2E300Q mutant consumed 2.0 ± 0.5 and 1.8 ± 0.1 min−1 in the absence and presence of DHX34D279A, respectively; and untagged RUVBL1E303Q-RUVBL2 mutant showed rates of 1.1 ± 0.5 and 0.5 ± 0.2 min−1 in the absence and presence of DHX34D279A, respectively) (Figure 5—figure supplement 3E–G).

Together, these results indicate that there is a correlation between the conformational changes induced by DHX34 and the ATP hydrolysis activity of the complex. Thus, DHX34 regulates ATP hydrolysis of the RUVBL1-RUVBL2 complex mostly by changes in the RUVBL2 subunit.

Discussion

Several lines of evidence show that the ATPase activity of RUVBL1 and RUVBL2 regulates several cellular processes. In particular, RUVBL1 and RUVBL2 ATPase activity is needed for a fully functional NMD response and for normal levels of SMG1-mediated UPF1 phosphorylation in vivo (Izumi et al., 2010; however, how these ATPases regulate NMD was completely unknown. Here, we provide evidence that RUVBL1 and RUVBL2 directly interact with a subset of factors involved in the initiation of the NMD response and these interactions can affect greatly the conformation of RUVBL1-RUVBL2 oligomers and their ATPase activity. RUVBL1-RUVBL2 hetero-hexameric complexes interact directly with SMG1 and also with DHX34, two factors involved in regulating NMD initiation. SMG1 is the kinase that phosphorylates UPF1, one of the key events that dictates that an mRNA is targeted for degradation; Kurosaki et al., 2019). In this work, we focused on the study of the complex between RUVBL1-RUVBL2 and DHX34, a novel interaction that we find in vitro and in cells in culture. DHX34 is an RNA helicase that binds SMG1 and UPF1 and promotes the interaction of UPF1 with UPF2 and UPF3b, UPF1 phosphorylation and the initiation of NMD (Hug and Cáceres, 2014; Melero et al., 2016). Interestingly, variants of DHX34 unable to facilitate UPF1 phosphorylation have been found as pathogenic versions specific to inherited forms of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (Rio-Machin et al., 2020).

The regulation of RUVBL1-RUVBL2 ATPase activity is poorly understood. The N-termini of RUVBL1 and RUVBL2 contain two histidine residues, His25 and His27 in RUVBL2, that bind the nucleotide and contribute to maintain it within its binding pocket (Muñoz-Hernández et al., 2019; Silva et al., 2018). Here, cryo-EM reveals that the NMD factor DHX34 directly affects the conformation of RUVBL2 N-termini and decreases ATP hydrolysis. DHX34 distorts the N-terminal regions in all three RUVBL2 subunits that are not visible in the map, an indication that they are flexible and not attached to the hexameric ring after DHX34 binding. Thus, these changes provide an exit route for nucleotides, which are lost in all the RUVBL2 subunits (Figure 5D). We find that DHX34 down-regulates the ATPase activity of the RUVBL1-RUVBL2 complex in vitro. Importantly, these effects are mediated exclusively by changes in RUVBL2 and not in RUVBL1, as shown by RUVBL2 ATPase-dead mutants not being sensible to DHX34. Together, these results show that DHX34 stabilizes a conformation of RUVBL2 unable to hydrolyze ATP.

Despite conformational changes occurring in RUVBL1 and RUVBL2, major changes and loss of nucleotide is only observed in the RUVBL2 subunits. It remains unclear how this translates to the function of the hexameric ring, but this argues in favor of a model where RUVBL1 and RUVBL2 perform different functions in the complex. Some evidence supports this model. Several reports indicate that RUVBL1 and RUVBL2 do not always share the same function in vivo (Mao and Houry, 2017). The ATPase activity of RUVBL2 is several fold higher than RUVBL1 at least when expressed separately (Nano et al., 2020), suggesting they do not function in the same way. Along the same lines, RUVBL2 shows several specialized functions in the context of the R2TP complex. RUVBL2 binds RPAP3 and PIH1D1, two subunits of the R2TP complex, functions not shared by RUVBL1. Interestingly, cordycepin, a derivative of the nucleoside adenosine affects the circadian clock in mammals by targeting RUVBL2 (Ju et al., 2020). A crystal structure of RUVBL1-RUVBL2 bound to cordycepin (PDB 6K0R) shows that the compound interacted with all RUVBL2 subunits but not with RUVBL1 and the N-termini of RUVBL2 were visible and folded into the protein. Therefore, it seems that RUVBL1 and RUVBL2 subunits could have specialized functions within the complex, maybe also in the context of NMD.

The role of RUVBL1-RUVBL2 ATPase activity in cells is not understood beyond the fact that ATP binding and/or hydrolysis is essential in vivo for all the cellular pathways in which this has been analyzed. Thus, what the regulation of their ATPase activity could mean for NMD in cells is completely unknown. Purified RUVBL1-RUVBL2 complexes display low but measurable ATPase activity, which suggests that the complex might not work as a molecular motor but rather as a switch regulated by the interaction of partners. Recent experiments showed that RUVBL1 and RUVBL2 could pull-down partners of the R2TP chaperone pathway more efficiently when an inhibitor of their ATPase activity is used (Yenerall et al., 2020). This was interpreted as an indication that RUVBL1-RUVBL2 may form more stable complexes in the absence of ATP hydrolysis and that hydrolysis could serve to disengage RUVBL1-RUVBL2 from its partners. The initiation of the NMD response requires the assembly of several transient macromolecular complexes involving core and auxiliary NMD factors (Hug et al., 2016; Kurosaki et al., 2019). Only when the right set of interactions has taken place, SMG1 kinase phosphorylates UPF1, which triggers a transition from an initial surveillance complex (SURF) to a decay-inducing complex (DECID) and mRNA decay. DHX34 interacts with both SMG1 and its substrate UPF1 and somehow promotes interactions with other NMD factors that activate UPF1 phosphorylation (Hug and Cáceres, 2014; Melero et al., 2016). We can speculate that RUVBL1-RUVBL2 could contribute to these events by providing a platform that facilitates some of this complex set of interactions, coupling their ATPase activity to the formation of some of the NMD complexes. The inhibition of RUVBL1-RUVBL2 ATP hydrolysis by DHX34 could maybe serve to stabilize this interaction while waiting for other NMD factors to bind DHX34 and RUVBL1-RUVBL2.

Together, our results reveal that DHX34, an NMD factor involved in NMD initiation, interacts directly with RUVBL1-RUVBL2 hetero-hexameric rings, profoundly modifying their structure and affecting their ATPase activity. This could help to couple RUVBL1-RUVBL2 ATPase activity to the assembly of the complexes required to initiate the NMD response.

Materials and methods

Transfections, immunoprecipitations, and western blotting

For interactions studies in cell extracts HEK293T cells were transfected with pcG-T7-DHX34 (WT and deletion mutants), pcDNA3-3xFLAG-UPF1 as described previously (Hug and Cáceres, 2014; Melero et al., 2016), pCDNA-3xHA-Reptin or pCDNA-3xFLAG-Pontin (Izumi et al., 2010; Rajendra et al., 2014; Venteicher et al., 2008) (Addgene plasmids), pcIneoFLAG-UPF2 (generous gift from Andreas Kulozik, Heidelberg) using Lipofectamine 2000 (Life Technologies) according to the manuals instructions. Cells were harvested and lysed 48 hr after transfection. Immunoprecipitation were performed, as previously described (Hug and Cáceres, 2014). Briefly, cells were lysed in IP buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM EGTA, 1% (v/v) NP-40, 0.2% (v/v) Na-Deoxycholate, Complete Protease Inhibitor (Roche), 1 mM dithiothreitol (DTT), 20 μg/ ml RNase A (ThermoScientific)). After Immunoprecipitations using T7 agarose (69026, MERCK Millipore), Anti-FLAG M2 Affinity Gel (A2220, Sigma-Aldrich) or antibodies against UPF1 (A300-038A, Bethyl) or UPF2 (sc-20227, Santa Cruz) coupled to protein G, immunoprecipitated proteins were separated by SDS-PAGE and detected by Western Blotting. RUVBL1 and RUVBL2 were detected with the following commercial antibodies: anti-Pontin (06–1299, Sigma Aldrich), anti-Reptin (SAB4200115, Sigma-Aldrich). FLAG and T7 affinity tags were detected with anti-FLAG (F3165, M2 clone, Sigma-Aldrich) and anti-T7 antibody (69522, Sigma Aldrich) respectively. The anti-DHX34 antibody has been previously described (Hug and Cáceres, 2014). Signals were detected with the ImageQuant LAS 4000 system (GE Healthcare) and quantified using the ImageQuant software.

Cell culture

HEK293T cells were grown in high glucose Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% (v/v) fetal calf serum (Life Technologies) and penicillin-streptomycin (Life Technologies) and incubated at 37°C in the presence of 5% CO2.

Cloning

For mapping experiments, a C-terminal His-tagged version of human RUVBL2 was produced. The cDNA of RUVBL2 (NM_006666) was PCR amplified from previously described pCDFDuet-1-RUVBL2 plasmid (López-Perrote et al., 2012) and inserted into pET21b vector (Novagen) using the IVA cloning system (García-Nafría et al., 2016), including 10 histidine residues at the C-terminus of the protein. RUVBL1 and RUVBL2 ATPase-dead mutants RUVBL1E303Q and RUVBL2E300Q unable to hydrolyze ATP were generated by site-directed mutagenesis of the original plasmids previously described (pETEV15b-RUVBL1 and pCDFDuet-1-RUVBL2) using standard protocols (López-Perrote et al., 2012). Oligonucleotides used for cloning are shown in Table 4.

Table 4. Oligonucleotides used for cloning.

Construct Name Sequence 5´- 3´
pET21b-RUVBL2_H10 pET21b_FW CACCACCACCACCACCACTG
RUVBL2_H10_FW ATGGCAACCGTTACAGCCACTGTTTAACTTTAAGAAGGAGATATACAT
RUVBL2_H10_RV GGAGGTGTCCATGGTCTCGCGTGGTGGTGGTGGTGATGGTGATGGTGAGGTCCCTGGAACAGCACCTCCAG
pET21b_RV ATGTATATCTCCTTCTTAAAGTTAAACAAAATT
pETEV15b-RUVBL1_E303Q R1_E303Q_FW AGGTCCACATGCTGG
R1_E303Q_RV CATGTGGACCTGATCAACAAACAGCACACC
pCDFDuet-1-RUVBL2_E300Q R2_E300Q_FW AGGTCCACATGCTGGAC
R2_E300Q_RV GCATGTGGACCTGGTCGATGAACAGCACTCC

Expression and purification of recombinant proteins in bacteria

RUVBL2 including C-terminal His-tag (RUVBL2-His) was expressed in BL21 (DE3) E. coli cells (NZYTech) grown in LB medium. Expression of the protein was induced by addition of IPTG (Isopropyl β-D-1-thiogalactopyranoside) at a final concentration of 0.1 mM at 28°C for 4 hr when cells reached an optical density (OD) of 0.5. Cells were collected by centrifugation at 8000 rpm during 10 min at 4°C, and the pellet was resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 300 mM NaCl, 10% (v/v) glycerol, 0.1% (v/v) NP-40) supplemented with a cocktail of proteases inhibitors (cOmplete EDTA-free, Roche) and lysozyme (final concentration 0.1 mg/ml) (Sigma-Aldrich). Cells were lysed by sonication and clarified by centrifugation at 35,000 rpm for 1 hr at 4°C. Supernant containing soluble proteins was filtered using a 0.45 μm device and applied to a HisTrap HP affinity column (GE Healthcare) equilibrated in buffer A (40 mM Tris-HCl pH 7.4, 200 mM NaCl, 10% (v/v) glycerol, 40 mM imidazole). Elution was performed using a gradient of increasing concentrations of imidazole with buffer B (40 mM Tris-HCl pH 7.4, 200 mM NaCl, 10% (v/v) glycerol, 500 mM imidazole). Fractions containing purified RUVBL2-His were pooled and dialyzed in buffer QA (40 mM Tris-HCl pH 7.4, 150 mM NaCl, 5% (v/v) glycerol) at 4°C during 16 hr. As a second purification step, dialyzed sample was applied on a HiTrap HP Q column (GE Healthcare) equilibrated in buffer QA and eluted in a gradient with increasing concentrations of NaCl using buffer QB (40 mM Tris-HCl pH 7.4, 1 M NaCl, 5% (v/v) glycerol). Fractions containing purified RUVBL2-His were dialyzed in buffer 40 mM Tris-HCl pH 7.4, 300 mM NaCl, 5% (v/v) glycerol at 4°C for 16 hr, freeze in liquid nitrogen, and storage at −80°C.

Expression and purification of His-RUVBL1 and His-RUVBL1-RUVBL2 complex were performed as previously described (López-Perrote et al., 2012). ATPase-dead mutants His-RUVBL1E303Q-RUVBL2, His-RUVBL1-RUVBL2E300Q, and His-RUVBL1E303Q-RUVBL2E300Q were expressed and purified using the same protocol as for wild-type RUVBL1-RUVBL2. Untagged RUVBL1-RUVBL2 complexes including ATPase-dead mutants were obtained by TEV protease digestion as previously described (López-Perrote et al., 2012). Untagged UPF1115-914 (UPF1 lacking residues 115–914 to increase protein stability), UPF2, UPF3b, and EJC (composed of eIF4AIII, Btz, MAGO and Y14 proteins) were produced as previously described (Melero et al., 2012). Chromatographic experiments were analyzed by 4–15% SDS-PAGE (MINI-PROTEAN TGX stain-free, Bio-Rad) and Quick Coomassie (Generon) staining.

Expression and purification of recombinant proteins in mammalian cells

SMG1-SMG8-SMG9 complex was produced in HEK293T cells following previously published protocols, including tandem FLAG-SBP-HA tags at the N-terminus of SMG1, and Strep-HA tags at the N-terminus of SMG8 and SMG9. The SBP-tag at the N-terminus of SMG1 was used for purification by affinity chromatography as described before (Melero et al., 2014).

3xFLAG-DHX34, either wild-type, ATPase mutant D279A, or the deletion mutant DHX34_ΔCTD (lacking residues 956–1143) were expressed in suspension HEK293GnTi- cells by transient transfection of the pCDNA vectors containing the different constructs of the DHX34 gene. Cells were grown in Freestyle 293 Expression Medium (Gibco) supplemented with 1% fetal bovine serum (FBS) in 5% CO2 and 95% humidity with agitation. 24 hr prior transfection, 500 ml of cells were seed at 0.8·106 cell/ml in 2L flasks. Transfection reagents were prepared by diluting 500 μg of the plasmids in Opti-MEM Reduced Serum Medium medium (Gibco), and after briefly mixing, 1500 μg PEI (Sigma-Aldrich) diluted in the same medium were added and further mixed. After 20 min incubation at room temperature, transfection mixtures were added to the cell cultures. Transfection was carried out for 48 hr in previously described grown conditions. Pellets for the transfected cells were collected by centrifugation at 2000 rpm for 10 min, washed twice with chilled PBS buffer, frozen in liquid nitrogen and stored at −80°C. For purification purposes, cells were resuspended in IP2 buffer (5 ml for 500 ml cell culture pellet) (10 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM EGTA, 1% (v/v) NP-40) supplemented with Benzonase Nuclease (EMD-Millipore), proteases inhibitors (cOmplete EDTA-free, Roche) and phosphatases inhibitors (PhosSTOP EASYpack, Roche). Cell lysis was performed by freezing/thawing in liquid nitrogen three times, and lysate was clarified by centrifugation at 35,000 rpm for 1 hr at 4°C.

Supernatant was incubated with ANTI-FLAG M2 affinity resin (Sigma-Aldrich) previously equilibrated in IP2 buffer for 2 hr at 4°C with agitation. Using spin columns (SigmaPrep spin columns, Sigma-Aldrich), resin was subjected to washing steps with five resin volumes each: with IP2 buffer two times, IP 1M buffer (IP2 buffer with 1 M NaCl), F buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1.2 mM EGTA, 250 mM sucrose, 1% (v/v) Triton X-100, 0.5% (v/v) NP-40 two times, F250 buffer) (F buffer supplemented with 250 mM LiCl), D buffer (20 mM HEPES pH 8, 100 mM KCl, 0.2 mM EDTA, 5% (v/v) glycerol, 0.5% (v/v) NP-40, and D400 buffer) (D buffer but with 400 mM KCl). Subsequently, the resin-bound protein was incubated with 5 mM ATP and 2 mM MgCl2 in TBS buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl) for 20 min at room temperature in order to remove contaminating HSP70 (as identified by liquid chromatography-mass spectroscopy), and further washed two times with buffer TBS. Elution was performed for 20 min at room temperature with TBS buffer supplemented with 3xFLAG peptide (Sigma-Aldrich) at a final concentration of 0.15 μg/ml.

For the reconstitution of the RUVBL1-RUVBL2-DHX34 complex for structural studies, ANTI-FLAG M2 affinity resin loaded with 3xFLAG-DHX34 and after the washes, was incubated with a 6-fold molar excess of purified His-RUVBL1-RUVBL2 diluted in TBS buffer, further washed four times with TBS buffer, and eluted with 3xFLAG peptide as indicated for the 3xFLAG-DHX34 purification. In some preparations, endogenous HSP70 chaperone was detected as a contaminant in the elution of the complex, but this could be removed by incubating DHX34-loaded beads with ATP and Mg2+ and subsequent washes in a buffer without nucleotide, prior to binding RUVBL1-RUVBL2.

In vitro pull-down experiments

In vitro interaction assays were performed using pull-down experiments with purified proteins. For histidine affinity pull-down of His-RUVBL1-RUVBL2 and NMD factors, 7.5 μM of His-RUVBL1-RUVBL2 (containing a 10 histidine tag at the N-terminus of RUVBL1 and wild-type RUVBL2) were mixed with 2-fold molar excess of either UPF1115-914, UPF2, UPF3b, EJC, SMG1-SMG8-SMG9 or DHX34 in 30 μl reactions in binding buffer (20 mM HEPES pH 7, 125 mM NaCl, 1 mM MgCl2, 10 mM imidazole, 2.5% (v/v) glycerol, 0.1% (v/v) NP-40). After 15 min incubation at 4°C, Ni-NTA agarose resin (Qiagen) previously equilibrated in binding buffer was added to the mixtures and further incubated for 30 min at 4°C with agitation. Mixtures were included on centrifugation columns (SigmaPrep spin columns, Sigma-Aldrich), and unbound proteins were washed times with 10 resin volumes of binding buffer supplemented with 50 mM imidazole, followed by elution with binding buffer supplemented with 500 mM imidazole. Inputs (2 μl) and elutions (10 μl) samples were analyzed by 4–15% SDS-PAGE (MINI-PROTEAN TGX stain-free, Bio-Rad) and staining with Quick Coomassie (Generon) or Oriole Fluorescent Gel Stain (Bio-Rad). Similar protocols were used in interactions assays between His-RUVBL1-RUVBL2 complex and 3xFLAG-DHX34_ΔCTD truncated mutant, and between either His-RUVBL1 (10 histidines tag at N-terminus) or RUVBL2-His (10 histidines tag at C-terminus) and 3xFLAG-DHX34.

For immunoaffinity pull-down experiments using FLAG or 3xFLAG tagged proteins, similar reaction mixtures were prepared for FLAG-SMG1-SMG8-SMG9 or 3xFLAG-DHX34 and His-RUVBL1-RUVBL2 complex. ANTI-FLAG M2 affinity resin (Sigma-Aldrich) previously equilibrated in TBS buffer was added to the mixtures and incubated for 2 hr at 4°C with agitation. After that, resin was washed 4 times with 10 resin volumes of TBS buffer, and elution was performed by incubation for 30 min at room temperature with TBS buffer supplemented with either FLAG peptide (for FLAG-tagged proteins) or 3xFLAG peptide (for 3xFLAG-tagged proteins) at a final concentration of 0.15 μg/ml.

Cryo-EM

3 μl of freshly purified RUVBL1-RUVBL2-DHX34 complex were applied to Quantifoil 300 mesh R1.2/1.3 grids after glow discharge, and the sample was flash frozen in liquid ethane using FEI Vitrobot MAG IV (Thermo Fisher Scientific). 3047 movies were collected in a Titan Krios at eBIC (Diamond Light Source, Oxford, UK) using a GATAN K2 Summit detector in counting mode, and a slit width of 20 eV on a GIF-Quantum energy filter. Cryo-EM images were collected as part of proposal EM20135 (Stop cancer - structural studies of macromolecular complexes involved in cancer by cryo-EM). Microscope calibrations and automatic data acquisition were performed with EPU software (Thermo Fisher Scientific) at a nominal magnification of ×47756, physical pixel size of 1.047 Å, a total dose of 48.1 e2, 6 e2/s, 40 fractions, and three images per hole. Autofocus was performed using an objective defocus range between −1.5 and −3.0 μm. The oligomeric state of RUVBL1-RUVBL2 ATPase dead-mutants His-RUVBL1E303Q-RUVBL2E300Q was analyzed by EM of negative stained samples. 3 μl microliters of freshly purified complexes (0.01 mg/ml) were deposited onto freshly glow-discharged carbon-coated 400 mesh copper electron microscopy (EM) grids (Electron Microscopy Sciences) and stained using 2% (w/v) uranyl acetate. Grids were visualized on a Tecnai 12 transmission electron microscope (Thermo Fisher Scientific Inc) with a lanthanum hexaboride cathode operated at 120 keV. Micrographs were recorded at x61320 nominal magnification and 2.5 A/pix on a 4k × 4 k TemCam-F416 CMOS camera (TVIPS).

Image processing

MotionCor2 was used for local drift correction (5 × 5 patches) and dose-weighting of fraction stacks (Zheng et al., 2017). Parameters for the contrast transfer function (CTF) of drift-corrected images were determined with Gctf (Zhang, 2016). A subset of manually picked particles was used to generate reference-free 2D averages in RELION (Zivanov et al., 2018) that were further used for template-based automatic particle picking using Gautomatch (K. Zhang, Yale University). Initial data set containing 353 057 particles was 2D-classified in RELION, and best quality particles were selected (121449). Ab initio 3D model was generated from the selected particles using cryoSPARC (Punjani et al., 2017), and used as reference for 3D-classification in RELION-3 (Zivanov et al., 2018). After some 2D classification to select the most homogenous sub-class, image processing was divided in two branches (Figure 2—figure supplement 1). To determine the structure of the full complex, we first classified the images using a mask to remove those particles with density too small to account for DHX34, obtaining a data sub-set of 41237 particles. These were classified in 3D and refined in RELION to generate a cryo-EM map with an estimated average resolution of 5.0 Å using gold-standard methods and the Fourier Shell Correlation (FSC) cut-off of 0.143. Due to the large difference in resolution within the map, showing high resolution in the AAA-ring and lower resolution in DHX34, the final volume was sharpened using LocalDeblur, an automatic local resolution-based sharpening, as implemented in Scipion (Ramírez-Aportela et al., 2020).

In a parallel branch, we removed the influence of DHX34 during image processing by using a mask in subsequent rounds of 3D classification and refinement. Refinement of the RUVBL1-RUVBL2 was initiated from a preliminary refinement step (containing 101774 particles) and it was performed using a mask that excluded the density for DHX34 as well as the external OB-fold domains of RUVBL1-RUVBL2. An estimated average resolution of 4.2 Å was obtained for the RUVBL1-RUVBL2 using gold-standard FSC cut-off of 0.143. Local resolution distribution of the cryo-EM maps was estimated using ResMap (Swint-Kruse and Brown, 2005) as implemented in RELION-3.

To analyze the structure of DHX34 in the complex, the density was subtracted from the particles in the final map using a mask, as implemented in RELION-3 (Zivanov et al., 2018). Density subtracted particles were first subjected to a consensus refinement and further 3D classification. Significant heterogeneity was observed in 3D classified volumes, but these maps were not able to be refined due to the reduced number of particles. From the consensus refinement, a mask was applied to the volume for local refinement, obtaining a structure with an estimated average resolution of 10.4 Å using gold-standard FSC cut-off of 0.143.

Negative staining EM micrographs obtained for His-RUVBL1E303Q-RUVBL2E300Q ATPase-dead mutants were used for extracting 55776 particles after CTF parameters estimation and correction, and 2D reference-free averages for each complex were obtained using cisTEM (Grant et al., 2018).

Atomic model building

Atomic model building on the high-resolution cryo-EM maps of the RUVBL1-RUVBL2 ATPase ring was performed using the human RUVBL1-RUVBL2 crystal structure as starting model (PDB 2XSZ). After an initial rigid fitting in USCF Chimera, manual refinement for all the six chains was done using Coot (Emsley et al., 2010). The quality of the maps allowed the modeling of the majority of the side chains in the ATPase core of RUVBL1-RUVBL2 and the identification of the empty nucleotide pockets in all the three RUVBL2 present in the hexamer. Some regions of the DII domains were not as well defined in all the subunits, and we used the information of the three copies of each subunit in the ring to solve some of the ambiguities during modeling. A final step of automatic refinement was done in phenix.real_space_refinement to improve the geometries of the model (Afonine et al., 2018).

ATPase assays

ATP hydrolysis by His-RUVBL1-RUVBL2 was measured in a continuous spectrophotometric pyruvate kinase-lactate dehydrogenase-coupled assay, based on the regeneration of the hydrolyzed ATP coupled to oxidation of NADH (Nørby, 1998). NADH absorbance at 340 nm was measured using a Jasco V-550 UV/VIS Spectrophotometer with a Jasco EHC-477T Temperature Controller and monitored using the ND-1000 and Spectra Manager software in time course experiments, and its decrease was used to determine ATP hydrolysis rates. Assays were performed at 37°C in 100 μl reactions in buffer 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 20 mM MgCl2, containing 2 mM phosphoenolpyruvate (PEP), 0.5 mM NADH, 0.04 U/μl pyruvate kinase/0.05 U/μl lactic dehydrogenase (Sigma-Aldrich) and 5 mM ATP. The reaction components without the protein of study where incubated for 10 min until stabilization of the absorbance at 340 nm to allow the system to regenerate contaminant ADP. ATP hydrolysis reactions were started by addition of 3 μM of His-RUVBL1-RUVBL2 (concentration calculated considering monomers), either wild-type or ATPase-dead mutants, and in the absence or presence of 1 μM DHX34D279A, and carried out for 20 min. We used the following ATPase-dead mutants: His-RUVBL1E303Q-RUVBL2, His-RUVBL1-RUVBL2E300Q and His-RUVBL1E303Q-RUVBL2E300Q. A similar set of the experiments were performed with untagged RUVBL1-RUVBL2 complexes (wild-type and ATPase-dead mutants) after removal of the histidine tag present in RUVBL1. We also performed control experiments using wild-type DHX34 and the DHX34D279A mutant, and only buffer. Assays were performed at least by triplicate. ATP turnover (mol ATP/mol protein) indicated in min−1 was calculated for a time interval during which the absorbance decrease was linear. Values in the graph are indicated as percentage of the rate of the wild-type protein.

Thermal stability determination

Samples thermostability was measured by nano differential scanning fluorimetry using a Tycho NT.6 instrument (NanoTemper Technologies) that measures the intrinsic fluorescence from tryptophan and tyrosine residues detected at emission wavelengths of 350 and 330 nm, as a 30°C · min−one thermal ramp is applied from 35°C to 95°C. The observed changes in fluorescence signal allows to monitor the unfolding process of the protein. The temperature at which a transition occurs, the inflection temperature (Ti), was determined by detecting the maximum of the first derivative of the fluorescence ratios (F350/F330) after fitting experimental data with a polynomial function.

Accession numbers

The cryo-EM maps of the RUVBL1-RUVBL2-DHX34 complex and the RUVBL1-RUVBL2 ring have been deposited in the EM database with accession codes EMD-11788 and EMD-11789 respectively. The structure of RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34 has been deposited as PDB ID 7AHO.

Acknowledgements

We acknowledge Diamond Light Source for access and support to the cryo-EM facilities at the UK's national Electron Bio-imaging Center (eBIC) under BAG proposal EM20135 (Stop cancer - structural studies of macromolecular complexes involved in cancer by cryo-EM), funded by the Wellcome Trust, MRC, and BBRSC. We acknowledge the use of the UCSF Chimera package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco. We thank Gianluca Degliesposti and Mark Skehel (MRC-LMB, UK) for preliminary analysis of the RUVBL1-RUVBL2-DHX34 complex using mass spectrometry. We thank Akio Yamashita and Shigeo Ohno from Yokohama City University (Japan) and Elena Conti from Max Planck Institute of Biochemistry (Germany, EU), for expression constructs and reagents. We also thank Dr Christos Savva from the Leicester Institute of Structural and Chemical Biology (UK), for initial data collection of the DHX34 complex. This work benefited from access to the Instruct Image Processing Center (I2PC, CNB-CSIC, Spain), an Instruct-ERIC centre, for image processing advice (PID: 10707).

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Oscar Llorca, Email: ollorca@cnio.es.

Andreas Martin, University of California, Berkeley, United States.

John Kuriyan, University of California, Berkeley, United States.

Funding Information

This paper was supported by the following grants:

  • Spanish Ministry of Science and Innovation SAF2017-82632-P to Andrés López-Perrote, Carlos F Rodríguez, Marina Serna, Oscar Llorca.

  • Autonomous Government of Madrid Y2018/BIO4747 to Ana González-Corpas, Oscar Llorca.

  • Autonomous Government of Madrid P2018/NMT4443 to Ana González-Corpas, Oscar Llorca.

  • MRC Core funding to Javier F Caceres.

  • Spanish Ministry of Science and Innovation BES-2015-071348 to Carlos F Rodríguez.

Additional information

Competing interests

No competing interests declared.

Author contributions

Investigation.

Investigation.

Investigation.

Investigation.

Investigation.

Investigation.

Investigation.

Investigation.

Conceptualization, Writing - review and editing.

Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing.

Additional files

Transparent reporting form

Data availability

The cryo-EM maps of the RUVBL1-RUVBL2-DHX34 complex and the RUVBL1-RUVBL2 ring have been deposited in the EM database with accession codes EMD-11788 and EMD-11789 respectively. The structure of RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34 has been deposited as PDB ID 7AHO.

The following datasets were generated:

Lopez-Perrote A, Rodriguez CF, Llorca O. 2020. RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34. RCSB Protein Data Bank. 7AHO

López-Perrote A, Rodríguez CF, Llorca O. 2020. Cryo-EM structure of the RUVBL1-RUVBL2-DHX34 complex. EMDataBank. EMD-11788

López-Perrote A, Rodríguez CF, Llorca O. 2020. RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34. EMDataBank. EMD-11789

References

  1. Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, Adams PD. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallographica Section D Structural Biology. 2018;74:531–544. doi: 10.1107/S2059798318006551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aramayo RJ, Willhoft O, Ayala R, Bythell-Douglas R, Wigley DB, Zhang X. Cryo-EM structures of the human INO80 chromatin-remodeling complex. Nature Structural & Molecular Biology. 2018;25:37–44. doi: 10.1038/s41594-017-0003-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheung KL, Huen J, Houry WA, Ortega J. Comparison of the multiple oligomeric structures observed for the Rvb1 and Rvb2 proteins. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 2010;88:77–88. doi: 10.1139/o09-159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallographica. Section D, Biological Crystallography. 2010;66:486–501. doi: 10.1107/S0907444910007493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eustermann S, Schall K, Kostrewa D, Lakomek K, Strauss M, Moldt M, Hopfner KP. Structural basis for ATP-dependent chromatin remodelling by the INO80 complex. Nature. 2018;556:386–390. doi: 10.1038/s41586-018-0029-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ewens CA, Su M, Zhao L, Nano N, Houry WA, Southworth DR. Architecture and Nucleotide-Dependent Conformational Changes of the Rvb1-Rvb2 AAA+ Complex Revealed by Cryoelectron Microscopy. Structure. 2016;24:657–666. doi: 10.1016/j.str.2016.03.018. [DOI] [PubMed] [Google Scholar]
  7. Feng Y, Tian Y, Wu Z, Xu Y. Cryo-EM structure of human SRCAP complex. Cell Research. 2018;28:1121–1123. doi: 10.1038/s41422-018-0102-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. García-Nafría J, Watson JF, Greger IH. IVA cloning: a single-tube universal cloning system exploiting bacterial in vivo assembly. Scientific Reports. 2016;6:srep27459. doi: 10.1038/srep27459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gat Y, Schuller JM, Lingaraju M, Weyher E, Bonneau F, Strauss M, Murray PJ, Conti E. InsP6 binding to PIKK kinases revealed by the cryo-EM structure of an SMG1-SMG8-SMG9 complex. Nature Structural & Molecular Biology. 2019;26:1089–1093. doi: 10.1038/s41594-019-0342-7. [DOI] [PubMed] [Google Scholar]
  10. Gorynia S, Bandeiras TM, Pinho FG, McVey CE, Vonrhein C, Round A, Svergun DI, Donner P, Matias PM, Carrondo MA. Structural and functional insights into a dodecameric molecular machine - the RuvBL1/RuvBL2 complex. Journal of Structural Biology. 2011;176:279–291. doi: 10.1016/j.jsb.2011.09.001. [DOI] [PubMed] [Google Scholar]
  11. Grant T, Rohou A, Grigorieff N. cisTEM, user-friendly software for single-particle image processing. eLife. 2018;7:e35383. doi: 10.7554/eLife.35383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Houry WA, Bertrand E, Coulombe B. The PAQosome, an R2TP-Based Chaperone for Quaternary Structure Formation. Trends in Biochemical Sciences. 2018;43:4–9. doi: 10.1016/j.tibs.2017.11.001. [DOI] [PubMed] [Google Scholar]
  13. Hug N, Longman D, Cáceres JF. Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Research. 2016;44:1483–1495. doi: 10.1093/nar/gkw010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hug N, Cáceres JF. The RNA helicase DHX34 activates NMD by promoting a transition from the surveillance to the decay-inducing complex. Cell Reports. 2014;8:1845–1856. doi: 10.1016/j.celrep.2014.08.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Izumi N, Yamashita A, Iwamatsu A, Kurata R, Nakamura H, Saari B, Hirano H, Anderson P, Ohno S. AAA+ proteins RUVBL1 and RUVBL2 coordinate PIKK activity and function in nonsense-mediated mRNA decay. Science Signaling. 2010;3:ra27. doi: 10.1126/scisignal.2000468. [DOI] [PubMed] [Google Scholar]
  16. Ju D, Zhang W, Yan J, Zhao H, Li W, Wang J, Liao M, Xu Z, Wang Z, Zhou G, Mei L, Hou N, Ying S, Cai T, Chen S, Xie X, Lai L, Tang C, Park N, Takahashi JS, Huang N, Qi X, Zhang EE. Chemical perturbations reveal that RUVBL2 regulates the circadian phase in mammals. Science Translational Medicine. 2020;12:eaba0769. doi: 10.1126/scitranslmed.aba0769. [DOI] [PubMed] [Google Scholar]
  17. Kurosaki T, Popp MW, Maquat LE. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nature Reviews Molecular Cell Biology. 2019;20:406–420. doi: 10.1038/s41580-019-0126-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lakomek K, Stoehr G, Tosi A, Schmailzl M, Hopfner KP. Structural basis for dodecameric assembly states and conformational plasticity of the full-length AAA+ ATPases Rvb1 · Rvb2. Structure. 2015;23:483–495. doi: 10.1016/j.str.2014.12.015. [DOI] [PubMed] [Google Scholar]
  19. Longman D, Plasterk RH, Johnstone IL, Cáceres JF. Mechanistic insights and identification of two novel factors in the C. elegans NMD pathway. Genes & Development. 2007;21:1075–1085. doi: 10.1101/gad.417707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. López-Perrote A, Muñoz-Hernández H, Gil D, Llorca O. Conformational transitions regulate the exposure of a DNA-binding domain in the RuvBL1-RuvBL2 complex. Nucleic Acids Research. 2012;40:11086–11099. doi: 10.1093/nar/gks871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lou C-H, Dumdie J, Goetz A, Shum EY, Brafman D, Liao X, Mora-Castilla S, Ramaiah M, Cook-Andersen H, Laurent L, Wilkinson MF. Nonsense-Mediated RNA Decay Influences Human Embryonic Stem Cell Fate. Stem Cell Reports. 2016;6:844–857. doi: 10.1016/j.stemcr.2016.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ludtke SJ, Baldwin PR, Chiu W. EMAN: semiautomated software for high-resolution single-particle reconstructions. Journal of Structural Biology. 1999;128:82–97. doi: 10.1006/jsbi.1999.4174. [DOI] [PubMed] [Google Scholar]
  23. Mao YQ, Houry WA. The role of Pontin and reptin in cellular physiology and Cancer etiology. Frontiers in Molecular Biosciences. 2017;4:58. doi: 10.3389/fmolb.2017.00058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Martino F, Pal M, Muñoz-Hernández H, Rodríguez CF, Núñez-Ramírez R, Gil-Carton D, Degliesposti G, Skehel JM, Roe SM, Prodromou C, Pearl LH, Llorca O. RPAP3 provides a flexible scaffold for coupling HSP90 to the human R2TP co-chaperone complex. Nature Communications. 2018;9:1501. doi: 10.1038/s41467-018-03942-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Matias PM, Gorynia S, Donner P, Carrondo MA. Crystal structure of the human AAA+ protein RuvBL1. The Journal of Biological Chemistry. 2006;281:38918–38929. doi: 10.1074/jbc.M605625200. [DOI] [PubMed] [Google Scholar]
  26. Maurizy C, Quinternet M, Abel Y, Verheggen C, Santo PE, Bourguet M, C F Paiva A, Bragantini B, Chagot ME, Robert MC, Abeza C, Fabre P, Fort P, Vandermoere F, M F Sousa P, Rain JC, Charpentier B, Cianférani S, Bandeiras TM, Pradet-Balade B, Manival X, Bertrand E. The RPAP3-Cterminal domain identifies R2TP-like quaternary chaperones. Nature Communications. 2018;9:1. doi: 10.1038/s41467-018-04431-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Melero R, Buchwald G, Castaño R, Raabe M, Gil D, Lázaro M, Urlaub H, Conti E, Llorca O. The cryo-EM structure of the UPF-EJC complex shows UPF1 poised toward the RNA 3' end. Nature Structural & Molecular Biology. 2012;19:498–505. doi: 10.1038/nsmb.2287. [DOI] [PubMed] [Google Scholar]
  28. Melero R, Uchiyama A, Castaño R, Kataoka N, Kurosawa H, Ohno S, Yamashita A, Llorca O. Structures of SMG1-UPFs complexes: smg1 contributes to regulate UPF2-dependent activation of UPF1 in NMD. Structure. 2014;22:1105–1119. doi: 10.1016/j.str.2014.05.015. [DOI] [PubMed] [Google Scholar]
  29. Melero R, Hug N, López-Perrote A, Yamashita A, Cáceres JF, Llorca O. The RNA helicase DHX34 functions as a scaffold for SMG1-mediated UPF1 phosphorylation. Nature Communications. 2016;7:10585. doi: 10.1038/ncomms10585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Muñoz-Hernández H, Pal M, Rodríguez CF, Fernandez-Leiro R, Prodromou C, Pearl LH, Llorca O. Structural mechanism for regulation of the AAA-ATPases RUVBL1-RUVBL2 in the R2TP co-chaperone revealed by cryo-EM. Science Advances. 2019;5:eaaw1616. doi: 10.1126/sciadv.aaw1616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nano N, Ugwu F, Seraphim TV, Li T, Azer G, Isaac M, Prakesch M, Barbosa LRS, Ramos CHI, Datti A, Houry WA. Sorafenib as an inhibitor of RUVBL2. Biomolecules. 2020;10:605. doi: 10.3390/biom10040605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Nasif S, Contu L, Mühlemann O. Beyond quality control: the role of nonsense-mediated mRNA decay (NMD) in regulating gene expression. Seminars in Cell & Developmental Biology. 2018;75:78–87. doi: 10.1016/j.semcdb.2017.08.053. [DOI] [PubMed] [Google Scholar]
  33. Nørby JG. Coupled assay of Na+,K+-ATPase activity. Methods in Enzymology. 1998;156:116–119. doi: 10.1016/0076-6879(88)56014-7. [DOI] [PubMed] [Google Scholar]
  34. Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nature Methods. 2017;14:290–296. doi: 10.1038/nmeth.4169. [DOI] [PubMed] [Google Scholar]
  35. Rajendra E, Garaycoechea JI, Patel KJ, Passmore LA. Abundance of the fanconi anaemia core complex is regulated by the RuvBL1 and RuvBL2 AAA+ ATPases. Nucleic Acids Research. 2014;42:13736–13748. doi: 10.1093/nar/gku1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ramírez-Aportela E, Vilas JL, Glukhova A, Melero R, Conesa P, Martínez M, Maluenda D, Mota J, Jiménez A, Vargas J, Marabini R, Sexton PM, Carazo JM, Sorzano COS. Automatic local resolution-based sharpening of cryo-EM maps. Bioinformatics. 2020;36:765–772. doi: 10.1093/bioinformatics/btz671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N, Wang J, Tummala H, Al Seraihi AFH, Alnajar J, Bewicke-Copley F, Armes H, Barnett M, Bloor A, Bödör C, Bowen D, Fenaux P, Green A, Hallahan A, Hjorth-Hansen H, Hossain U, Killick S, Lawson S, Layton M, Male AM, Marsh J, Mehta P, Mous R, Nomdedéu JF, Owen C, Pavlu J, Payne EM, Protheroe RE, Preudhomme C, Pujol-Moix N, Renneville A, Russell N, Saggar A, Sciuccati G, Taussig D, Toze CL, Uyttebroeck A, Vandenberghe P, Schlegelberger B, Ripperger T, Steinemann D, Wu J, Mason J, Page P, Akiki S, Reay K, Cavenagh JD, Plagnol V, Caceres JF, Fitzgibbon J, Dokal I. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature Communications. 2020;11:1044. doi: 10.1038/s41467-020-14829-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rivera-Calzada A, Pal M, Muñoz-Hernández H, Luque-Ortega JR, Gil-Carton D, Degliesposti G, Skehel JM, Prodromou C, Pearl LH, Llorca O. The structure of the R2TP complex defines a platform for recruiting diverse client proteins to the HSP90 molecular chaperone system. Structure. 2017;25:1145–1152. doi: 10.1016/j.str.2017.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Silva STN, Brito JA, Arranz R, Sorzano CÓS, Ebel C, Doutch J, Tully MD, Carazo JM, Carrascosa JL, Matias PM, Bandeiras TM. X-ray structure of full-length human RuvB-Like 2 - mechanistic insights into coupling between ATP binding and mechanical action. Scientific Reports. 2018;8:13726. doi: 10.1038/s41598-018-31997-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Swint-Kruse L, Brown CS. Resmap: automated representation of macromolecular interfaces as two-dimensional networks. Bioinformatics. 2005;21:3327–3328. doi: 10.1093/bioinformatics/bti511. [DOI] [PubMed] [Google Scholar]
  41. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases Pontin and reptin as telomerase components essential for holoenzyme assembly. Cell. 2008;132:945–957. doi: 10.1016/j.cell.2008.01.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yenerall P, Das AK, Wang S, Kollipara RK, Li LS, Villalobos P, Flaming J, Lin YF, Huffman K, Timmons BC, Gilbreath C, Sonavane R, Kinch LN, Rodriguez-Canales J, Moran C, Behrens C, Hirasawa M, Takata T, Murakami R, Iwanaga K, Chen BPC, Grishin NV, Raj GV, Wistuba II, Minna JD, Kittler R. RUVBL1/RUVBL2 ATPase activity drives PAQosome maturation, DNA replication and radioresistance in lung Cancer. Cell Chemical Biology. 2020;27:105–121. doi: 10.1016/j.chembiol.2019.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zhang K. Gctf: real-time CTF determination and correction. Journal of Structural Biology. 2016;193:1–12. doi: 10.1016/j.jsb.2015.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zheng SQ, Palovcak E, Armache J-P, Verba KA, Cheng Y, Agard DA. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zhu L, Li L, Qi Y, Yu Z, Xu Y. Cryo-EM structure of SMG1-SMG8-SMG9 complex. Cell Research. 2019;29:1027–1034. doi: 10.1038/s41422-019-0255-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, Scheres SH. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166. doi: 10.7554/eLife.42166. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision letter

Editor: Andreas Martin1
Reviewed by: Andreas Martin2

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

This study provides the first structural and biochemical evidence that RuvBL1/RuvBL2 directly interacts with the RNA helicase DHX34, suggesting a potential mechanism for the previously described activity of this AAA ATPase in the initiation of nonsense-mediated mRNA decay (NMD). The presented cryo-EM structure reveals how DHX34 binding to the RuvBL1/RuvBL2 heterohexamer induces a conformational change of RuvBL2's N-terminus and consequently modulates nucleotide binding and hydrolysis in every other subunit of the ATPase ring, potentially acting as a switch in orchestrating the assembly of NMD factors.

Decision letter after peer review:

[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]

Thank you for submitting your work entitled "Regulation of RUVBL1-RUVBL2 AAA-ATPases by the nonsense-mediated mRNA decay factor DHX34, as evidenced by Cryo-EM" for consideration by eLife. Your article has been reviewed by three peer reviewers, including Andreas Martin as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by a Senior Editor.

As you will see in the individual reviews, there are a number of issues and weaknesses, both, for the structure determination and the biochemical characterization, and with several of them consistently picked up by multiple reviewers. Our decision has been reached after consultation between the reviewers, and based on these discussions and the individual reviews below, we regret to inform you that your work cannot be considered for publication in eLife at this point. However, reviewers agreed that the manuscript is potential interesting, and we invite you re-submit your manuscript after the critical corrections, analyses, and additional experiments have been completed.

Reviewer #1:

López-Perrote and colleagues present the structure of DHX34-bound RUVBL1-RUVBL2, which is implicated in nonsense-mediated mRNA decay (NMD). This structure demonstrates how DHX34 uses most of its domains to interact with the internal regions of the DII domains in both RUVBL1 and RUVBL2, and causes large conformational changes in the RUVBL1-RUVBL2 hexamer, in particular the ATPase domain of RUVBL2. DHX34 is identified as a potential regulator of RUVBL1-RUVBL2's ATPase activity, which represents an important step in determining the mechanisms underlying the initiation of NMD.

However, before this manuscript can be considered for publication in eLife, the authors should address several concerns, as outlined below.

Major Points:

1) The authors suggest that oligomerization of RUVBL1 and RUVBL2 hampers nucleotide exchange, yet this model seems not sufficiently supported by the data and the authors should adjust their discussion in this respect.

The ATP-binding pocket is located between neighboring protomers, with critical motifs contributed by both AAA domains, such that monomeric RUVBL1 and RUVBL2 are not capable of ATP hydrolysis. The comparison between hexamer and monomer is therefore unnecessary, and proposing that hexamerization lowers the ATP-hydrolysis rate does not make much sense. In fact, the subunit interface between RUVBL1 and RUVBL2 appears highly similar to that of other AAA+ motors, and it is in my opinion unlikely that the pocket itself "traps" the nucleotide and prevents exchange. At the various stages of the ATPase cycle (or positions in the hexameric ring), individual subunits of numerous other AAA+ hexamers show differential opening and closure of their nucleotide-binding sites. Depending on the averaging for the RUVBL1-RUVBL2 structure, subunits may appear uniformly closed, which, however, is not necessarily inconsistent with hydrolysis activity. What could contribute to the low rates, as suggested by the authors and previous studies, are the N-termini of RUVBL1/2 that seem to contact the nucleotide and in the case of RuvBL2 get released upon binding of DHX34. Given the minimal ATPase rate of 1 per min, RUVBL1/2 may indeed not work as a processive ATPase, but only as a switch that could get triggered by DHX34. In that respect this new structure is very interesting.

2) The overall analysis of nucleotide occupancies is problematic, considering that the resolution is not high enough to confidently assign nucleotides to each site.

The inherent averaging that occurs in single-particle cryo-EM image processing may very well explain the absence of detectable nucleotide in all RUVBL2 pockets of the DHX34-bound complex. As observed for many other cryo-EM structures of AAA+ motors, nucleotide pockets are highly dynamic and often less well resolved compared to the rest of the structure. Whether binding of DHX34 indeed induces a 3-fold symmetric state of the hexamer in which all 3 RUVBL2 sites are nucleotide free remains questionable. Building the class averages was likely determined by the asymmetric DHX34 density above the ring, and if the orientation of DHX34 is not well correlated with the nucleotide occupancy in a particular RuvBL2 subunit, averaging particles based on DHX34 could make it look like all 3 RuvBL2 sites are empty or lower in nucleotide density, whereas in reality it may be just one. If this were the case, the structure would resemble other AAA+ motors that show a small gap in the hexameric ring flanked by a nucleotide-free "seam" subunit, while all other subunits represent a continuum of nucleotide states.

To better evaluate the local resolution of the nucleotide pockets, it is necessary to have a zoomed-in view of these pockets on the ResMap of the 4.18Å RUVBL1-RUVBL2 hexameric ring (Figure 3—figure supplement 2D), highlighting the ADPs in RUVBL1. It is important to know the local resolution for these pockets, because based on the current evidence, the map alone may not provide enough detail to accurately assign nucleotides. One way to address this is by doing a more thorough analysis of the pockets themselves, including the overall size, shape, and location of key hydrolysis residues in comparison to known hydrolysis states of these pockets.

For example, in both Figure 4E and 4F it would be helpful to include labels of hydrolysis-relevant residues, like Arginine fingers and Walker A/B motifs, such that readers can easily orient themselves. In Figure 4E, the pocket looks just as "open" in the ATP-bound state (2XSZ) as in the DHX34-bound structure, and it is important to explain why this is considered a nucleotide-free rather than ADP- or ATP-bound state. Are there retracted residues that make this pocket incompetent for nucleotide binding? And could an ATP possibly fit into the RUVBL1 pocket? The current thresholding in Figure 4F does not exclude this possibility. It would also be appropriate to include the N-terminal histidines that directly interact with ADP in RUVBL1, as this may provide further evidence that it is indeed an ADP.

In general, it may be worth processing the data again and building class averages while masking out DHX34 to assess whether the hexamer indeed adopts a clear 3-fold symmetric state.

3) Regarding the very low ATPase rate of just 1 min-1, one potential issue may be that RUVBL1/2 was not purified in the presence of ATP and an ATP regeneration system. There are several examples of AAA+ motors that irreversibly lose robust activity when purified in the absence of ATP, and it may be worth testing whether RUVBL1/2 shows higher activities when purified in ATP.

The NADH consumption shown in Figure 5A is not linear, but increases over the 30 min measurements (30 – 60 min) for both, RUVBL1/2 and the DHX34-bound complex. What is the reason for that and what do the traces look like between the addition of RUVBL1/2 and the 30 min mark? The regeneration of ADP present in the RUVBL1/2 sample at the time of mixing should be completed within a couple of seconds, and temperature equilibration is expected to take only a couple of minutes. Non-linear absorbance changes over tens of minutes and a slow acceleration indicate that the system was not at steady state, which could also be consistent with the AAA+ motor being trapped in an inhibited state due to purification in the absence of ATP.

The authors discuss a model where ATP hydrolysis may regulate the interactions of RUVBL1/2 with other partners during NMD initiation, and the more stable binding of RUVBL1/2 to partners of the R2TP chaperone pathway in the absence of ATP hydrolysis is mentioned as an example. Similar effects have indeed been observed for various other AAA+ motors whose interactions are more dynamic during ATP hydrolysis. For RUVBL1/2, how does the very low ATPase activity of 1 min-1 compare to the off rate of its binding partners?

The authors propose that the ATPase inhibition of RUVBL1/2 by DHX34 may stabilize complexes. However, according to the presented model, DHX34 binding induces nucleotide release from every other site in the hexamer, which is expected to have distinct or even opposite effects compared to preventing hydrolysis and trapping hexamers in permanent ATP-bound states.

It is also suggested that DHX34 binding fully eliminates ATP hydrolysis (and even nucleotide interactions) in the RUVBL2 sites, while RUVBL1 "continues hydrolyzing at comparable levels to those measured in the absence of HBX34". This would mean that ATPase subunits in the hexamer are completely independent in their ATP hydrolysis, with no communication between neighbors. Although this is not ruled out, it has to my knowledge not been reliable described for other AAA+ hexamers, which usually show coordinated transitions and subunit communications that are mediated by arginine fingers and various other interactions within the topologically-closed rings. In fact, the ATPase rates for the single Walker-B mutants RUVBL1(E303Q)-RUVBL2 and RUVBL1-RUVBL2(E318Q) do not show 50% lower activity, but a reduction by 80 or 75% (Figure 5—figure supplement 1B) compared to wild type, suggesting that there is indeed communication between neighboring subunits.

The authors may consider further investigating this, for instance by characterizing hexamers with Walker-A or Walker-B mutations in RUVBL2, or an Arginine-finger mutation in RUVBL1 in the presence and absence of HDX34. If the authors' model is correct, the ATPase activity of these RUVBL1/2 variants should not respond to DHX34 binding and be similar to that of DHX34-bound wild-type RUVBL1/2.

Reviewer #2:

Lopez-Perrote et al. show that RUVBL1-RUVBL2 participates in the nonsense-mediated mRNA decay (NMD) pathway through direct interaction with the DHX34 RNA helicase. The authors present a cryo-EM structure of the complex, as well as pulldowns and functional assays that indicate DHX34 affects the conformation and activity of RUVBL1-RUVBL2.

Is there any indication of stoichiometry of DHX34 binding beside the triangular shape of the DHX34 density in the map (in Figure 3 and Figure 3—figure supplement 3)? The homology model fit into the map (in Figure 3—figure supplement 3) is unconvincing as there are clear helical densities in the map that appear not to fit any of the homology model helices. Overall, the homology model and experimental map do not appear to be in good agreement. Could more than one DHX34 be binding? The map and model in their current form do not seem sufficient to answer this question.

It seems surprising that the deletion of any of the domains of DHX34 (Figure 3—figure supplement 4C) results in no loss of binding to RUVBL1-RUVBL2. This observation is particularly surprising because it suggests that any domain can be deleted without affecting the folding or soluble expression of DHX34. It is not clear from this experiment that there is a definitive threshold for "loss of binding".

Further, the large variance in signal in the western blot appears to indicate that there could be a dependence on certain domains to bind (for instance RecA1), but the threshold for "no binding" is defined poorly. The authors should likely revise or modify the conclusion that this experiment supports the binding of all domains of DXH34 to RUVBL1-RUVBL2.

It is unclear if the 50% inhibition seen is due to incomplete binding of RUVBL1-RUVBL2 by DHX34 or if that 50% inhibition is an inherent property of the complex between the two.

Reviewer #3:

The work described in this manuscript is potentially of interest but is not ready for publication in its present form for a number of reasons. While it may be difficult (impossible?) for additional lab work to be conducted at present, this should not mean that incomplete studies are suitable for publication.

1) The experiments in Figure 1 Panel D are done by mixing components in solution and allowing them to come to some sort of equilibrium. This can lead to results that are not easy to interpret correctly in the absence of appropriate controls. For example, the amount of RvbL1/2 is not constant across the 2nd gel (compare lanes 10 and 11), which suggests a problem. If the whole RvbL/SMG1/RPAP3/PIH1D1 complex is unable to be bound to the resin, then an amount will remain in solution in samples with RPAP3/PIH1D1. This is not the same result as competing for sites on RvbLs, this is competition between Rvbs and RPAP3-PIH1D1 for a site or sites on SMG1-8-9. Alternatively, a complex between SMG complex or its components and RPAP3-PIH1D1 would not stick to the resin but might prevent binding of RvbLs to SMG1. Pull downs using the FLAG tag would provide a necessary control (i.e. repeating part (C) but in the presence of RPAP3-PIH1D1). However, it would also need to be shown that SMG8-9 does not interact with RPAP3-PIH1D1 as well.

Also, in the final lane (lane 14) all bands are more intense than even the 1:4 ratio lane (lane 13), which could be consistent with a portion of RPAP3/PIH1D1 remaining in solution (e.g. bound to SMG complex or a component of it) when the SMG complex is present. It also needs to be stated somewhere what the concentration on RPAP3-PIH1D1 is in lanes 2, 7, 9 and 14. From the gel band densities in the input it would appear to be 1:4.

Consequently, the data cannot distinguish between at least three different situations (a) competition between SMG1 and RPAP3-PIH1D1 for RvbL hexamer, (b) both binding simultaneously (as discussed by authors), or (c) binding of RPAP3-PIH1D1 to some component of SMG complex that then precludes binding of either to RvbL hexamer. These alternatives need to be distinguished for these data to be of any value.

In fact, since these data have no relevance to the rest of the paper they could be deleted. If they are included, then they need to be improved e.g. by cryoEM to show whether SMG1-Rvb complex is hexamer or dodecamer and/or where SMG1 is located. In their present form the data are not convincing without further validation and/or suitable controls.

2) For the cryoEM study, it is not clear to me why after the Rvb component was masked off so a 4.2Å structure could be obtained, this was not then used to subtract the Rvb density to allow a better local refinement of the DHX34 component? This could improve the DHX34 density dramatically. The observation that the Rvb hexamer density improves so much when the DHX34 component is removed, suggests that there is enough signal from that part to cause the misalignment of the RvbL hexamer so should be sufficient to allow refinement of that part alone, even if that requires several conformational classes to be defined.

3) For the ATPase inhibition experiments there are a number of issues.

First, why do the activity traces begin at 30mins rather than time zero? The rates should be shown from the start of ATP turnover, initiated by, for example, addition of ATP or magnesium after allowing an incubation period for components to form complexes if necessary.

Second, the rates are not linear but are curves. The whole point of the coupled assay is that the ATP is regenerated so remains at a constant level and therefore the rates should be linear unless other factors such as subunit association/disassociation are occurring that mean the system is not at equilibrium. Unless the rates are linear then they are meaningless because they are not steady state. Which part of these curves were measured to estimate the rates? The Materials and methods section suggests an amount after 30 mins was determined, presumably simply a difference over that time? Which time interval? Obviously, this is not accurate or appropriate for a rate that is curving. Interesting, in every assay shown, the curves are getting faster showing the rates are getting quicker as time progresses. This needs to be explained, particularly for DHX34.

Third, the experiments need to address whether it is the Vmax for the reaction that has altered or whether affinity for ATP is different. Furthermore, the structure raises the intriguing possibility that the rate may be halved because only half of the ATPase sites are now active i.e. those in the RvbL1 subunits. The authors have already created the tools to follow this up biochemically by making so-called Walker B mutants for each RvbL subunit. If it is indeed the RvbL2 subunits that are inactivated by the helicase binding, then binding should have no, or lesser, effect on the ATPase activity in the RvbL1/RvbL2EQ hexamer while the RvbL1EQ/RvbL2 hexamer should show a more dramatic effect than wildtype RvbL1/RvbL2 hexamers, or even complete inhibition of activity.

eLife. 2020 Nov 18;9:e63042. doi: 10.7554/eLife.63042.sa2

Author response


[Editors’ note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors’ response to the first round of review.]

Reviewer #1:

López-Perrote and colleagues present the structure of DHX34-bound RUVBL1-RUVBL2, which is implicated in nonsense-mediated mRNA decay (NMD). This structure demonstrates how DHX34 uses most of its domains to interact with the internal regions of the DII domains in both RUVBL1 and RUVBL2, and causes large conformational changes in the RUVBL1-RUVBL2 hexamer, in particular the ATPase domain of RUVBL2. DHX34 is identified as a potential regulator of RUVBL1-RUVBL2's ATPase activity, which represents an important step in determining the mechanisms underlying the initiation of NMD.

However, before this manuscript can be considered for publication in eLife, the authors should address several concerns, as outlined below.

Major Points:

1) The authors suggest that oligomerization of RUVBL1 and RUVBL2 hampers nucleotide exchange, yet this model seems not sufficiently supported by the data and the authors should adjust their discussion in this respect.

The ATP-binding pocket is located between neighboring protomers, with critical motifs contributed by both AAA domains, such that monomeric RUVBL1 and RUVBL2 are not capable of ATP hydrolysis. The comparison between hexamer and monomer is therefore unnecessary, and proposing that hexamerization lowers the ATP-hydrolysis rate does not make much sense. In fact, the subunit interface between RUVBL1 and RUVBL2 appears highly similar to that of other AAA+ motors, and it is in my opinion unlikely that the pocket itself "traps" the nucleotide and prevents exchange. At the various stages of the ATPase cycle (or positions in the hexameric ring), individual subunits of numerous other AAA+ hexamers show differential opening and closure of their nucleotide-binding sites. Depending on the averaging for the RUVBL1-RUVBL2 structure, subunits may appear uniformly closed, which, however, is not necessarily inconsistent with hydrolysis activity. What could contribute to the low rates, as suggested by the authors and previous studies, are the N-termini of RUVBL1/2 that seem to contact the nucleotide and in the case of RuvBL2 get released upon binding of DHX34.

The reviewer is right that our initial version of the manuscript did not clearly explain the consequences of RUVBL1 and RUVBL2 oligomerization. We would like to emphasize that our statement indicating that “oligomerization of RUVBL1 and RUVBL2 hampers nucleotide exchange” was not directly drawn from our data, but rather an elaboration based on previous results found in the literature

Crystal structure of the human AAA+ protein RuvBL1. Matias et al., 2006

Some relevant quotes from this paper stated

In an attempt to understand the weak ATPase activity of wild-type RuvBL1, we undertook a more detailed comparison between the nucleotide binding pockets of RuvBL1 and of other AAA+ proteins with known ATPase activity in vitro; (…) The results of this comparison are listed in Table 3 and show that RuvBL1 has the lowest solvent-accessible area among all these molecules, indicating in this case a very tightly bound ADP unit. Therefore, it cannot easily exchange with ATP, and this may be the cause for the low in vitro ATPase activity of RuvBL1. In addition, the adenine ring of ADP is held in place by a large number of hydrogen bonds and hydrophobic contacts, and both phosphate groups also have a large number of hydrogen bonds.

Hexamer formation does not appear to influence ADP binding, since the capping of the nucleotide binding pocket by an adjacent monomer does not alter the solvent-accessible area calculations. However, it does obstruct a possible ADP exit channel and, thus, contributes to prevent the ADP/ATP Exchange.

The three-dimensional structure of RuvBL1 reveals an ADP molecule tightly bound between DI and DIII and that access to the ATPase active site is additionally blocked by hexamerization, thereby making the exchange between ADP and ATP impossible. Additional cofactors are, therefore, likely to be needed to open the nucleotide pocket.

We agree with the reviewer that it is unlikely that the pocket itself could trap the nucleotide and it is probably that the N-termini of RUVBL1 and RUVBL2 regulates RUVBL1-RUVBL2 complexes.

Furthermore, our use of the terms “open” and “close” was not accurate, since we used it to refer to the absence of N-termini, where the access to the nucleotide binding pocket seems more exposed (“open”) compared to when the N-termini is shown in contact with the nucleotide (“closed”). We never intended to imply that the actual conformation of the nucleotide binding pockets was “open” or “closed”. We have now removed these terms and clarify this in the revised version.

Altogether, we have now extensively revised the appropriate Sections, mainly in the Introduction and in the Discussion.

Our revised conclusion is that DHX34 regulates hydrolysis by altering the N-termini of RUVBL2 that contact the nucleotide.

Given the minimal ATPase rate of 1 per min, RUVBL1/2 may indeed not work as a processive ATPase, but only as a switch that could get triggered by DHX34. In that respect this new structure is very interesting.

This is indeed interesting, and it is now mentioned in the Introduction and Discussion sections of the revised version. We have also commented on some recent manuscript that contains some new information about their rates of ATP hydrolysis (Nano et al., 2020).

2) The overall analysis of nucleotide occupancies is problematic, considering that the resolution is not high enough to confidently assign nucleotides to each site.

The inherent averaging that occurs in single-particle cryo-EM image processing may very well explain the absence of detectable nucleotide in all RUVBL2 pockets of the DHX34-bound complex. As observed for many other cryo-EM structures of AAA+ motors, nucleotide pockets are highly dynamic and often less well resolved compared to the rest of the structure. Whether binding of DHX34 indeed induces a 3-fold symmetric state of the hexamer in which all 3 RUVBL2 sites are nucleotide free remains questionable. Building the class averages was likely determined by the asymmetric DHX34 density above the ring, and if the orientation of DHX34 is not well correlated with the nucleotide occupancy in a particular RuvBL2 subunit, averaging particles based on DHX34 could make it look like all 3 RuvBL2 sites are empty or lower in nucleotide density, whereas in reality it may be just one. If this were the case, the structure would resemble other AAA+ motors that show a small gap in the hexameric ring flanked by a nucleotide-free "seam" subunit, while all other subunits represent a continuum of nucleotide states.

We agree with this analysis made by the reviewer although we respectfully disagree we cannot confidentially assign nucleotides to each state. Some of the image processing suggested by the reviewer was actually done in the manuscript, which means that we did not explain well in the text and figures.

In the revised version we have clarified these key points but we have also performed additional experiments in accordance with the suggestions, to address these issues in full.

1) The reviewer mentions that the resolution is not sufficient to confidentially assign nucleotide.

We believe this not to be correct

a) Resolution at the nucleotide binding sites is around 4 Angstroms, which is sufficient to observe density for the nucleotides (see new Figure 3—figure supplement 1).

b) In this work, the structure of the RUVBL1-RUVBL2-DHX34 contains an internal control, since we can see nucleotides in RUVBL1 at the resolutions reached, and importantly the resolution is similar for both RUVBL1 and RUVBL2 subunits (see new Figure 3—figure supplement 1). Density for the nucleotide is clearly seen in RUVBL1 and clearly absent in RUVBL2, strongly supporting that there is nucleotide in all RUVBL1 subunits but not in RUVBL2 subunits.

Thus, in our opinion, the resolution of our map is sufficient to clearly detect nucleotides in RUVBL1 and we have a similar resolution in RUVBL2. (Issues about the influence of our image processing on the occupancy are mentioned below).

In the revised version we now show in detail the density in the cryo-EM map for the nucleotide-binding pockets of all 6 subunits of the complex showing clear density for the nucleotide in RUVBL1 subunits and clear absence of density in RUVBL2 subunits in new Figure 3—figure supplement 1.

2) Averaging may explain the absence of detectable nucleotide and class averages were determined by the asymmetric DHX34 density.

We agree with the reviewer that this can happen and this is why we used an image processing strategy designed to avoid it. We describe the structure of the full RUVBL1-RUVBL2-DHX34 complex in Figure 2, and then the structure of the RUVBL1-RUVBL2 ring at higher resolution in Figure 3. The structure of RUVBL1-RUVBL2 in Figure 3 was determined after masking out the density of DHX34 at very initial stages of refinement to remove any influence of DHX34 in the alignment and avoid the issues mentioned by the reviewer.

In summary, the reviewer is right, but we actually performed an image processing strategy to avoid the influence of DHX34 by masking out its density during refinement. Now we have clarified this in Results and Materials and methods section, but we have also modified the workflow of the image processing in the supplementary figures to clarify this (Figure 2—figure supplement 1).

3) New image processing and experiments to address this issue in full

We agree with the reviewer that it is critical to rule out that the lack of occupancy in all 3 RUVBL2 subunits is not an artifact of our image processing strategy.

Thus, in the revised version:

a) Additional image processing of the RUVBL1-RUVBL2-DHX34 complex:

After refinement of the RUVBL1-RUVBL2 ring masking out DHX34, we have now classified the particles in 3D to search for potential heterogeneity in nucleotide occupancy. As suggested above by the reviewer, we followed the state of each subunit by presence or absence of the histidine containing N-termini, a clear structural feature at this resolution level. This analysis, shown on Figure 3—figure supplement 3 did not detect any particles with different nucleotide occupancy.

b) Since the reviewer raised the issue that some of our conclusions could be influenced by the averaging of particles with a different level of nucleotide occupancy at the same location, we also analyzed the final RUVBL1-RUVBL2 structure by 3D classification of each of the 3 RUVBL1-RUVBL2 dimers in the structure independently. Each dimer in the final refinement step was classified without further alignment and masking out all other regions in the ring to search for heterogeneity. In all three dimers the vast majority of the particles displayed a clear conformation where the N-termini is present in RUVBL1 and absent in RUVBL2.

This analysis strongly suggested that for a great majority of particles, all RUVBL1-2 dimers have similar nucleotide occupancy. This analysis is now shown on Figure 3—figure supplement 4.

c) To further strengthen the results described in 3.2, we also analyzed our data using a symmetry expansion strategy as described before (Martino et al., 2018; Zhou et al., 2015). Briefly, because each RUVBL1-RUVBL2 complex has a roughly threefold symmetry we rotated each particle around the 3-fold symmetry axis three times to place all RUVBL1RUVBL2 dimers in the same position. This operation triplicated the data set and then we placed a mask around one of the dimers Particles were then subjected to a local classification strategy to look for heterogeneity in the nucleotide occupancy of each RUVBL1-RUVBL2 pair, regardless of each position in the ring. This is now shown in Figure 3—figure supplement 5, and confirms that the great majority of RUVBL1-RUVBL2 dimers have density for the N-terminus in RUVBL1 but not RUVBL2.

d) We have now performed ATPase experiments with several RUVBL1-RUVBL2 mutants that are compatible with an effect of DHX34 in all RUVBL2 subunits but not in RUVBL1 (see below and in response also to other reviewers)

Altogether, we believe that by clarifying the image processing performed by masking out DHX34 and all the new experiments described above, we have addressed the issue of the nucleotide occupancy in full.

To better evaluate the local resolution of the nucleotide pockets, it is necessary to have a zoomed-in view of these pockets on the ResMap of the 4.18Å RUVBL1-RUVBL2 hexameric ring (Figure 3—figure supplement 2D), highlighting the ADPs in RUVBL1. It is important to know the local resolution for these pockets, because based on the current evidence, the map alone may not provide enough detail to accurately assign nucleotides. One way to address this is by doing a more thorough analysis of the pockets themselves, including the overall size, shape, and location of key hydrolysis residues in comparison to known hydrolysis states of these pockets.

The reviewer is right. We have now modified Figure 3 to show details of the nucleotide binding pockets in RUVBL1 and RUVBL2 comparing our structure with previous crystal structures. As mentioned above, DHX34 affected mostly the N-termini of RUVBL2 but not significantly the nucleotide binding pockets themselves, as incorrectly implied in the previous version of the manuscript by using the terms “open” and “closed”. This has now been corrected.

Resolution at the nucleotide binding sites is around 4 Angstroms, which is sufficient to observe density for the nucleotides, and as suggested we now show the local resolution of the pockets themselves as well as detailed map in the new Figure 3—figure supplement 1.

For example, in both Figure 4E and 4F it would be helpful to include labels of hydrolysis-relevant residues, like Arginine fingers and Walker A/B motifs, such that readers can easily orient themselves. In Figure 4E, the pocket looks just as "open" in the ATP-bound state (2XSZ) as in the DHX34-bound structure, and it is important to explain why this is considered a nucleotide-free rather than ADP- or ATP-bound state. Are there retracted residues that make this pocket incompetent for nucleotide binding? And could an ATP possibly fit into the RUVBL1 pocket? The current thresholding in Figure 4F does not exclude this possibility. It would also be appropriate to include the N-terminal histidines that directly interact with ADP in RUVBL1, as this may provide further evidence that it is indeed an ADP.

The reviewer is right and all this information has now been included in the revised version, in the new Figure 3. We previously used the term “open” to refer to the disappearance of the N-termini of RUVBL2 that facilitates the accessibility to the nucleotide pockets. We now think that this term is not very adequate because it might be interpreted as implying that the nucleotide pocket itself was more open, which is not what happens. We have now modified the revised version and clarify our findings, and we also make a comparison of the nucleotide pockets of RUVBL1 and RUVBL2 before and after binding to DHX34.

In general, it may be worth processing the data again and building class averages while masking out DHX34 to assess whether the hexamer indeed adopts a clear 3-fold symmetric state.

As described above, we believe we have now addressed the issues regarding the occupancy if RUVBL1 and RUVBL2 subunits by nucleotide.

3) Regarding the very low ATPase rate of just 1 min-1, one potential issue may be that RUVBL1/2 was not purified in the presence of ATP and an ATP regeneration system. There are several examples of AAA+ motors that irreversibly lose robust activity when purified in the absence of ATP, and it may be worth testing whether RUVBL1/2 shows higher activities when purified in ATP.

The rates that we find for RUVBL1-RUVBL2 (4.9 mol ATP/mol protein·min) are in the same range that all previous works with these proteins, such as those found in Gorynia et al., 2011 (0.56 mol ATP/mol protein·min) and Lakomek et al., 2015 (3 mol ATP/mol protein·min). Interestingly, a recent work analyzed the ATPase activity of RUVBL1 and RUVBL2 separately, observing that the activity of RUVBL2 is 8-fold higher than RUVBL1 (Nano et al., 2020).

RUVBL1-RUVBL2 complexes co-purify with nucleotide regardless of these not been present during purification. This has been observed in all structures solved till now where nucleotide, mostly ADP, but sometimes also ATP, fill every subunit in the complex. We think, in agreement with all previous reports, that these ATPases have an intrinsic low ATPase rate.

The NADH consumption shown in Figure 5A is not linear, but increases over the 30 min measurements (30 – 60 min) for both, RUVBL1/2 and the DHX34-bound complex. What is the reason for that and what do the traces look like between the addition of RUVBL1/2 and the 30 min mark? The regeneration of ADP present in the RUVBL1/2 sample at the time of mixing should be completed within a couple of seconds, and temperature equilibration is expected to take only a couple of minutes. Non-linear absorbance changes over tens of minutes and a slow acceleration indicate that the system was not at steady state, which could also be consistent with the AAA+ motor being trapped in an inhibited state due to purification in the absence of ATP.

We apologize since we did not explain well the details of how we performed the ATPase experiments. The method we performed has been used by others to measure the activity of other ATPases and also of RUVBL1 and RUVBL2 (Nano et al., 2020). We have now clarified these issues.

We previously indicated that this experiment took place during 60 min in total, but it should be noted that the first 10 minutes were a pre-incubation time without the ATPase to allow the system to regenerate possible contaminant ADP present in the reagents, and not the reaction itself. We calculated rates of ATP consumption by averaging for a 30 min interval (from minute 30 to minute 60) during which the absorbance decrease was adjusted to a linear function.

In any case, we have decided to repeat and improve these experiments, at the same time that some mutants were also analyzed.

For this revised version:

– In our curves, linearity was lost only at the end experiment at 37ºC. We suspect that this could be due to the instability of DHX34. In our hands, DHX34 activity is affected over time upon storage and it might be possible that it is also affected after a long period at 37º. To investigate this, we have now analyzed the stability of DHX34 using nano differential scanning fluorimetry, a technique that measures the intrinsic fluorescence of the protein during a thermal ramp denaturation experiment. We found that DHX34 is stable during 20 min incubation at 37ºC but not at longer times (Figure 5—figure supplement 1), so accordingly experiments have been run for only 20 min.

– We have repeated the experiments for 20 min and NADH consumptions are now linear (Figure 5—figure supplement 2).

– We have clarified our methodology in Materials and methods.

The authors discuss a model where ATP hydrolysis may regulate the interactions of RUVBL1/2 with other partners during NMD initiation, and the more stable binding of RUVBL1/2 to partners of the R2TP chaperone pathway in the absence of ATP hydrolysis is mentioned as an example. Similar effects have indeed been observed for various other AAA+ motors whose interactions are more dynamic during ATP hydrolysis. For RUVBL1/2, how does the very low ATPase activity of 1 min-1 compare to the off rate of its binding partners?

As mentioned, current evidences suggest that the low ATPase activity of RUVBL1-RUVBL2 could be related to its function as a switch in different macromolecular complexes, but not as a processive motor ATPase. In several pathways, such as NMD, protein-protein interactions are transient due the dynamics of the process, and signals from others partners are needed for rearrangement steps to allow the remodeling of the complexes. RUVBL1-RUVBL2 ATPase activity could have an impact on such signals, allowing assembly and/or disassembly of intermediate complexes.

The authors propose that the ATPase inhibition of RUVBL1/2 by DHX34 may stabilize complexes. However, according to the presented model, DHX34 binding induces nucleotide release from every other site in the hexamer, which is expected to have distinct or even opposite effects compared to preventing hydrolysis and trapping hexamers in permanent ATP-bound states.

At this stage we do not know what the function of the regulation of RUVBL1-RUVBL2 activity by DHX34 in the context of NMD is. Our speculation is based on recent findings showing that an allosteric inhibitor of RUVBL1-RUVBL2 ATPase activity stabilizes their interaction with clients of the PIKK assembly pathway in cells. Since DHX34 reduces hydrolysis, this could have a similar effect as the inhibitor described. Having said that, this is very speculative and we modified the Discussion section to give less strength to this educated guess.

It is also suggested that DHX34 binding fully eliminates ATP hydrolysis (and even nucleotide interactions) in the RUVBL2 sites, while RUVBL1 "continues hydrolyzing at comparable levels to those measured in the absence of HBX34". This would mean that ATPase subunits in the hexamer are completely independent in their ATP hydrolysis, with no communication between neighbors. Although this is not ruled out, it has to my knowledge not been reliable described for other AAA+ hexamers, which usually show coordinated transitions and subunit communications that are mediated by arginine fingers and various other interactions within the topologically-closed rings. In fact, the ATPase rates for the single Walker-B mutants RUVBL1(E303Q)-RUVBL2 and RUVBL1-RUVBL2(E318Q) do not show 50% lower activity, but a reduction by 80 or 75% (Figure 5—figure supplement 1B) compared to wild type, suggesting that there is indeed communication between neighboring subunits.

The authors may consider further investigating this, for instance by characterizing hexamers with Walker-A or Walker-B mutations in RUVBL2, or an Arginine-finger mutation in RUVBL1 in the presence and absence of HDX34. If the authors' model is correct, the ATPase activity of these RUVBL1/2 variants should not respond to DHX34 binding and be similar to that of DHX34-bound wild-type RUVBL1/2.

We agree with the reviewer that we cannot conclude that DHX34 affects only RUVBL2 sites with the data available in our first version of the manuscript. To make things more complex, recent evidence shows that RUVBL2 subunits might be more active than RUVBL1 subunits (Nano et al., 2020). Therefore, calculations on the ratio of reduction of activity after adding DHX34 are not sufficient to relate the observed phenomena to either RUVBL1 or RUVBL2 subunits.

To address this issue, we have performed the experiments suggested by the reviewer which are part of the new Figure 5 and its supplemental figures:

– We generated RUVBL1 and RUVBL2 double mutants unable to bind nucleotide, and we used them to purify RUVBL1-RUVBL2 complexes with one or both subunits mutated. As a control, we analyzed the complex by electron microscopy before performing experiments (Figure 5—figure supplement 1A, B). To our surprise, we were unable to find the well-characterized hexameric top views, and complexes appeared as heterogeneous in size and shape. Other groups have found before that ADP or ATP could help the assembly of recombinant RUVBL2, and we interpreted that assembly of recombinant hexameric complexes is affected when nucleotide cannot bind to both subunits.

– We then focused on RUVBL1 and RUVBL2 mutations that are affected in ATP hydrolysis but not ATP binding. Complexes containing one or both subunits mutated were purified and their correct assembly verified using electron microscopy.

– We also tested the ATPase activity of the different mutants in the absence and presence of DHX34. This information is now found in Figure 5 and fully confirms that DHX34 affects only RUVBL2, since DHX34 effects are only detected in complexes containing wildtype RUVBL2 but not ATPase-dead RUVBL2 mutants.

A key point to our work was that the effects of DHX34 on ATP hydrolysis correlate well with the conformational changes observed in RUVBL2 but not RUVBL1 subunits. The new experiments added a strong support this conclusion.

Reviewer #2:

Lopez-Perrote et al. show that RUVBL1-RUVBL2 participates in the nonsense-mediated mRNA decay (NMD) pathway through direct interaction with the DHX34 RNA helicase. The authors present a cryo-EM structure of the complex, as well as pulldowns and functional assays that indicate DHX34 affects the conformation and activity of RUVBL1-RUVBL2.

Is there any indication of stoichiometry of DHX34 binding beside the triangular shape of the DHX34 density in the map (in Figure 3 and Figure 3—figure supplement 3)? The homology model fit into the map (in Figure 3—figure supplement 3) is unconvincing as there are clear helical densities in the map that appear not to fit any of the homology model helices. Overall, the homology model and experimental map do not appear to be in good agreement. Could more than one DHX34 be binding? The map and model in their current form do not seem sufficient to answer this question.

The reviewer is right that the homology model does not fit the structure of the complex, and we indicated this in the text. We have removed this fitting experiment in the manuscript since, we agree with the reviewer, it does not provide a sufficiently useful information.

To determine the stoichiometry of the RUVBL1-RUVBL2 complex:

1) We have extracted the densities for DHX34 from the map of the complex. These images were processed to obtain a cryo-EM map of DHX34 processed independently of RUVBL1-RUVBL2. Although resolution was poor given the limited number of images, insufficient for such a small and flexible protein, this map was useful to compare with the structure of isolated DHX34 from negative stain microscopy. This comparison suggested that only one molecule of DHX34 was bound to RUVBL1-RUVBL2.

2) In addition, we estimated the mass of this volume as 120 kDa using the “volume” programme from EMAN (see text for details).

Together these results indicate that only one DHX34 binds to each RUVBL1-RUVBL2 and that we only probably visualize the core of the protein and not the flexible C-terminal domain. Details can be found in the final section of Results and in the new Figure 4—figure supplement 1

It seems surprising that the deletion of any of the domains of DHX34 (Figure 3—figure supplement 4C) results in no loss of binding to RUVBL1-RUVBL2. This observation is particularly surprising because it suggests that any domain can be deleted without affecting the folding or soluble expression of DHX34. It is not clear from this experiment that there is a definitive threshold for "loss of binding".

Further, the large variance in signal in the western blot appears to indicate that there could be a dependence on certain domains to bind (for instance RecA1), but the threshold for "no binding" is defined poorly. The authors should likely revise or modify the conclusion that this experiment supports the binding of all domains of DXH34 to RUVBL1-RUVBL2.

The DHX34 mutants we used were designed and selected by our collaborators in Edinburgh (Nele Hug and Javier F Caceres). In our previous collaborative study, we showed that they soluble and maintain certain functional properties (Melero et al., 2016). Here, we made use of these already tested mutants to analyze their effect on DHX34 binding.

We agree with the reviewer that it is surprising that we do not have larger effects in some mutants. This could be partially due to the difficulty to confidentially detect small differences but maybe also to the possible influence of additional factors for the RUVBL1-RUVBL2-DHX34 interaction in cells, such as the contribution of additional NMD proteins.

We have now repeated these experiments and quantified the effect of individual domains of DHX34 and larger deletions covering several domains in the binding to RUVBL1-RUVBL2 (new Figure 4).

It is unclear if the 50% inhibition seen is due to incomplete binding of RUVBL1-RUVBL2 by DHX34 or if that 50% inhibition is an inherent property of the complex between the two.

The reviewer is right. In addition, recent evidence shows that RUVBL2 subunits might be more active than RUVBL1 subunits (Nano et al., 2020). Therefore, calculations on the ratio of reduction of activity after adding DHX34 are not sufficient to relate the observed phenomena to either RUVBL1 or RUVBL2 subunits.

To address this issue, we have made used of RUVBL1 and RUVBL2 mutant unable to hydrolysis ATP, and measure the influence of adding DHX34. Complexes containing one or both subunits mutated were purified and their correct assembly verified using electron microscopy. We then tested the ATPase activity of the different mutants in the absence and presence of DHX34.This information is now found in Figure 5 and its supplemented figures and fully confirms that DHX34 affects only RUVBL2, since DHX34 effects are only detected in complexes containing wildtype RUVBL2 but not ATPase-dead RUVBL2 mutants.

A key point to our work was that the effects of DHX34 on ATP hydrolysis correlate with the conformational changes observed in RUVBL2 but not RUVBL1 subunits. The new experiments added in Figure 5 strongly support this conclusion.

Reviewer #3:

The work described in this manuscript is potentially of interest but is not ready for publication in its present form for a number of reasons. While it may be difficult (impossible?) for additional lab work to be conducted at present, this should not mean that incomplete studies are suitable for publication.

We agree with this reviewer and we have followed the criticisms and concerns raised by all three reviewers to be able to present a more complete study. Despite the very challenging situation due to the current pandemic, we believe that we have managed to do this, and we have revised our manuscript extensively, incorporated new data, and also revised the text. We believe that the revised version of the manuscript has addressed the issues raised by the reviewers.

1) The experiments in Figure 1 Panel D are done by mixing components in solution and allowing them to come to some sort of equilibrium. This can lead to results that are not easy to interpret correctly in the absence of appropriate controls. For example, the amount of RvbL1/2 is not constant across the 2nd gel (compare lanes 10 and 11), which suggests a problem. If the whole RvbL/SMG1/RPAP3/PIH1D1 complex is unable to be bound to the resin, then an amount will remain in solution in samples with RPAP3/PIH1D1. This is not the same result as competing for sites on RvbLs, this is competition between Rvbs and RPAP3-PIH1D1 for a site or sites on SMG1-8-9. Alternatively, a complex between SMG complex or its components and RPAP3-PIH1D1 would not stick to the resin but might prevent binding of RvbLs to SMG1. Pull downs using the FLAG tag would provide a necessary control (i.e. repeating part (C) but in the presence of RPAP3-PIH1D1). However, it would also need to be shown that SMG8-9 does not interact with RPAP3-PIH1D1 as well.

Also, in the final lane (lane 14) all bands are more intense than even the 1:4 ratio lane (lane 13), which could be consistent with a portion of RPAP3/PIH1D1 remaining in solution (e.g. bound to SMG complex or a component of it) when the SMG complex is present. It also needs to be stated somewhere what the concentration on RPAP3-PIH1D1 is in lanes 2, 7, 9 and 14. From the gel band densities in the input it would appear to be 1:4.

Consequently, the data cannot distinguish between at least three different situations (a) competition between SMG1 and RPAP3-PIH1D1 for RvbL hexamer, (b) both binding simultaneously (as discussed by authors), or (c) binding of RPAP3-PIH1D1 to some component of SMG complex that then precludes binding of either to RvbL hexamer. These alternatives need to be distinguished for these data to be of any value.

In fact, since these data have no relevance to the rest of the paper they could be deleted. If they are included, then they need to be improved e.g. by cryoEM to show whether SMG1-Rvb complex is hexamer or dodecamer and/or where SMG1 is located. In their present form the data are not convincing without further validation and/or suitable controls.

We agree with the reviewer that the SMG1 interaction data is disconnected from the rest of the manuscript, which is focused on the interaction between RUVBL1-RUVBL2 and DHX34. We have now removed this from the revised version, including the competition experiments using RPAP3PIH1D1, which were a concern for this reviewer.

Nonetheless, we have left the main RUVBL1-RUVBL2-SMG1 interaction experiment as part of supplemental information in the context of the interaction experiments of RUVBL1-RUVBL2 with most factors involved in NMD initiation.

2) For the cryoEM study, it is not clear to me why after the Rvb component was masked off so a 4.2Å structure could be obtained, this was not then used to subtract the Rvb density to allow a better local refinement of the DHX34 component? This could improve the DHX34 density dramatically. The observation that the Rvb hexamer density improves so much when the DHX34 component is removed, suggests that there is enough signal from that part to cause the misalignment of the RvbL hexamer so should be sufficient to allow refinement of that part alone, even if that requires several conformational classes to be defined.

We have tried again to improve the structure of DHX34 as suggested (Figure 4—figure supplement 1), but without success, possibly because the number of particles is not sufficiently large for a small protein. All these new analyses are part of Figure 4—figure supplement 1 and one section of results. In addition, we have compared our low-resolution map of DHX34 when bound to RUVBL1-RUVBL2 with the low-resolution map of DHX34 obtained in isolation. This, and other analysis, suggests that the stoichiometry of the RUVBL1-RUVBL2-DHX34 complex is 3:3:1.

3) For the ATPase inhibition experiments there are a number of issues.

Some of the issues about the ATPase experiments mentioned by the reviewer have their origin in our lack of adequate explanations on how the experiments were conducted, and how our results were represented. We have now addressed this in full by providing significant more details in the Materials and methods section and by relating our experiments to a recent work that measures the ATPase activity of RUVBL1 and RUVBL2 using the same protocols we use.

First, why do the activity traces begin at 30mins rather than time zero? The rates should be shown from the start of ATP turnover, initiated by, for example, addition of ATP or magnesium after allowing an incubation period for components to form complexes if necessary.

Second, the rates are not linear but are curves. The whole point of the coupled assay is that the ATP is regenerated so remains at a constant level and therefore the rates should be linear unless other factors such as subunit association/disassociation are occurring that mean the system is not at equilibrium. Unless the rates are linear then they are meaningless because they are not steady state. Which part of these curves were measured to estimate the rates? The Materials and methods section suggests an amount after 30 mins was determined, presumably simply a difference over that time? Which time interval? Obviously, this is not accurate or appropriate for a rate that is curving. Interesting, in every assay shown, the curves are getting faster showing the rates are getting quicker as time progresses. This needs to be explained, particularly for DHX34.

In our experiments, reaction components of the pyruvate kinase-lactate dehydrogenase-coupled assay and the RUVBL1-RUVBL2 and DHX34 protein complexes were incubated separately for 10 min at 37 ºC for stabilization. This step was done to allow the system to regenerate possible contaminant ADP from the reagents, so the ATPase reaction starts from a stable baseline. Then, the RUVBL1-RUVBL2 and DHX34 protein are added to the reaction to initiate hydrolysis, and the measurements were taken for additionally 50 min. The experiment took place during 60 min in total, but the first 10 minutes were the pre-incubation time, not the ATP hydrolysis reaction per se. This was not properly explained in the previous version of the manuscript. We calculated rates of ATP consumption by averaging for a 30 min interval during which the absorbance decrease was adjusted to a linear function (from minute 30 to minute 60). Similar approach has been used before (Nano et al., 2020). But the selection of the interval was arbitrary as long as rates were linear and we decided then to represent in the graphs maintaining the original numbering of minutes in our experiment. We have now repeated all the ATPase experiments in the manuscript, and in addition to new experiments using several RUVBL1 and RUVBL2 mutants. We have now clarified how the experiment was performed, and we now consider as time zero when the mix was performed but removing the first minute where the measurement is distorted by the opening and closing of the Jasco V-550 UV/VIS Spectrophotometer.

For this revised version:

– In our curves, linearity was lost only at the end experiment at 37ºC. We suspect that this could be due to the instability of DHX34. In our hands, DHX34 activity is affected over time upon storage and it might be possible that it is also affected after a long period at 37º. To investigate this, we have now analyzed the stability of DHX34 using nano differential scanning fluorimetry, a technique that measures the intrinsic fluorescence of the protein during a thermal ramp denaturation experiment, and we found that DHX34 is stable during 20 min incubation at 37ºC but not at longer times, so experiments have been run for only 20 min (Figure 5—figure supplement 1).

– We have repeated the experiments for 20 min after the mixing and NADH consumptions are now linear (Figure 5—figure supplement 2).

– We have clarified our methodology in the Materials and methods section.

All these changes are now part of Figure 5 and its supplemental figures and a more detailed version of Materials and methods.

Third, the experiments need to address whether it is the Vmax for the reaction that has altered or whether affinity for ATP is different. Furthermore, the structure raises the intriguing possibility that the rate may be halved because only half of the ATPase sites are now active i.e. those in the RvbL1 subunits. The authors have already created the tools to follow this up biochemically by making so-called Walker B mutants for each RvbL subunit. If it is indeed the RvbL2 subunits that are inactivated by the helicase binding, then binding should have no, or lesser, effect on the ATPase activity in the RvbL1/RvbL2EQ hexamer while the RvbL1EQ/RvbL2 hexamer should show a more dramatic effect than wildtype RvbL1/RvbL2 hexamers, or even complete inhibition of activity.

Recent evidence shows that RUVBL2 subunits might be more active than RUVBL1 subunits (Nano et al., 2020). Therefore, calculations on the ratio of reduction of activity after adding DHX34 are not sufficient to relate the observed phenomena to either RUVBL1 or RUVBL2 subunits. To address this issue, we have made use of RUVBL1 and RUVBL2 mutant unable to hydrolysis ATP, and have measured the influence of adding DHX34. Complexes containing one or both subunits mutated were purified and their correct assembly verified using electron microscopy. We then tested the ATPase activity of the different mutants in the absence and presence of DHX34. This information is now found in Figure 5 and full confirms that DHX34 affects only RUVBL2, since DHX34 effects are only detected in complexes containing wildtype RUVBL2 but not ATPase-dead RUVBL2 mutants.

A key point to our work was that the effects of DHX34 on ATP hydrolysis correlate with the conformational changes observed in RUVBL2 but not RUVBL1 subunits. The new experiments added strongly support this conclusion.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Lopez-Perrote A, Rodriguez CF, Llorca O. 2020. RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34. RCSB Protein Data Bank. 7AHO
    2. López-Perrote A, Rodríguez CF, Llorca O. 2020. Cryo-EM structure of the RUVBL1-RUVBL2-DHX34 complex. EMDataBank. EMD-11788
    3. López-Perrote A, Rodríguez CF, Llorca O. 2020. RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34. EMDataBank. EMD-11789

    Supplementary Materials

    Figure 5—source data 1. Source data for the ATPase activity assays shown in Figure 5, Figure 5—figure supplement 1, Figure 5—figure supplement 2 and Figure 5—figure supplement 3' and the caption to 'The file includes 15 sheets, each one for 1 sample, containing the replicas done for the sample.

    In each sheet is included: Name of sample, time (min), absorbance at 340 nm for the replicas, equation of the linear regression trendline for each replica used for data analysis, and R2 value of the linear regression trendline for each replica.

    Transparent reporting form

    Data Availability Statement

    The cryo-EM maps of the RUVBL1-RUVBL2-DHX34 complex and the RUVBL1-RUVBL2 ring have been deposited in the EM database with accession codes EMD-11788 and EMD-11789 respectively. The structure of RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34 has been deposited as PDB ID 7AHO.

    The following datasets were generated:

    Lopez-Perrote A, Rodriguez CF, Llorca O. 2020. RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34. RCSB Protein Data Bank. 7AHO

    López-Perrote A, Rodríguez CF, Llorca O. 2020. Cryo-EM structure of the RUVBL1-RUVBL2-DHX34 complex. EMDataBank. EMD-11788

    López-Perrote A, Rodríguez CF, Llorca O. 2020. RUVBL1-RUVBL2 heterohexameric ring after binding of RNA helicase DHX34. EMDataBank. EMD-11789


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES